



Center for Vaccine Ethics & Policy (CVEP)
Vaccines and Global Health: The Week in Review
01 August 2026 :: Issue 856

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

Milestones, Perspectives

.....
.....

USG – Gavi Support

Editor's Note:

We present the full text of the joint announcement by the U.S. State Department and Department of HHS to release all the USD\$600M funding to Gavi already approved by Congress for 2025-26. The announcement lists a number of commitments and actions that Gavi has agreed to undertake as a condition for the release of funds and notes that the U.S. will resume a seat on Gavi's board "...to hold Gavi accountable for measurable progress toward these commitments."

We also present the Gavi acknowledgement of and thanks for the USG action. It is noteworthy that the Gavi announcement makes no reference to any of the stipulations or characterizations of the commitments detailed in the USG announcement.

We did encounter reporting in *Health Policy Watch* – [Gavi Welcomes Restoration of US Funding – But No Clarity on How Agency will Phase out Thimerosal](#), 30/07/2026 – which includes Gavi positioning on some of the commitments referenced in the USG announcement.

U.S. Department of State and U.S. Department of Health and Human Services on Strengthening Vaccine Safety, Accountability, and American Leadership in Global Health

Media Note July 29, 2026

The United States is committed to advancing global health in a manner that reflects American interests, scientific integrity, and accountability to the American people. Under President Trump's leadership, the United States has made clear that American taxpayer dollars must support transparent, evidence-based programs that deliver measurable health outcomes.

Last year, President Trump directed Secretary of Health and Human Services Robert F. Kennedy, Jr. and Secretary of State Marco Rubio to engage directly with Gavi, the Vaccine Alliance (Gavi), and **secure meaningful reforms before the United States would consider future support.**

Those discussions resulted in **significant commitments that strengthen vaccine safety, improve public health, and better align Gavi's work with the principles of Gold Standard Science and transparency. Based on those commitments, the United States will immediately release all \$600 million in Congressionally appropriated funds to Gavi for both FY25 and FY26.**

Gavi has committed to work towards transitioning mercury-containing vaccines and expanding access to newer, mercury-free alternatives. Specifically, in partnership with Gavi's Board and countries, Gavi will make every effort to:

- transition mercury-containing meningococcal A vaccines with mercury-free vaccines that protect against additional meningococcal strains;
- transition mercury-containing pentavalent DTP-Hib-HepB vaccines to mercury-free hexavalent vaccines that also protect against polio;
- transition mercury-containing pneumococcal vaccines to mercury-free vaccines that protect against additional pneumococcal strains; and
- transition mercury-containing hepatitis B vaccines to mercury-free alternatives.

The Administration believes reducing reliance on mercury-containing vaccines, where suitable alternatives are available, is a pro-vaccine, pro-innovation policy. The United States and the European

Union removed mercury from most childhood vaccines 25 years ago. As of June 2025, CDC's Advisory Committee on Immunization Practices no longer recommends any mercury-containing vaccines. Children in Africa, Asia, and Latin America deserve access to the same higher-quality, mercury-free vaccines, and these changes will also expand protection against additional disease strains.

Achieving these transitions will require manufacturers to expand production capacity, countries to adopt newer vaccine formulations, and **Gavi's governing Board to complete the necessary approvals. The United States recognizes these implementation challenges but welcomes Gavi's commitment to work toward these goals through transparent governance and responsible stewardship.**

Gavi has already implemented additional reforms requested by the United States including:

- Ending the promotion and procurement of COVID-19 vaccines for routine immunization programs; and
- Finalizing extensive operational reforms including the reorganization and downsizing of staff in Geneva and instituting a partnership accountability framework that decreases funding for and reforms Gavi's engagement with other partners, including the World Health Organization (WHO).

Gavi has further committed to establishing an integrated and dedicated Secretariat function to monitor and review developments in vaccine science, including vaccine safety.

In addition, given the sizeable contribution the United States is making to improve access to vaccines, **the United States expects to resume its place on the Gavi Board.** In this role, the United States will continue to hold Gavi accountable for measurable progress toward these commitments. It will evaluate any future U.S. support based on demonstrated performance, accountability, and implementation of these reforms.

The United States also reaffirms that it will not provide U.S. Government funding to the World Health Organization through Gavi.

President Trump has made clear that American leadership in global health must be rooted in accountability, scientific excellence, and measurable results. The Department of Health and Human Services and the Department of State will continue to ensure that U.S. global health programs and partnerships uphold Gold Standard Science, rigorous independent review, transparency, responsible stewardship of taxpayer resources, and better health outcomes around the world.

.....

[Gavi welcomes United States government commitment to unlock funding for fiscal years 2025 and 2026](#)

Geneva, 30 July 2026 – Gavi, the Vaccine Alliance welcomes the announcement today by the United States Government that it intends to release US\$ 600 million in funding appropriated by Congress for Gavi for fiscal years 2025 and 2026.

This vital funding will help fill critical gaps in vaccine access for countries and continues a long history of partnership between Gavi and the United States – reflecting our shared commitment to saving lives, strengthening defenses against infectious disease outbreaks, and accelerating the rollout of powerful new vaccines.

"We are deeply grateful to the United States for this commitment to unlock funding to Gavi," said Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance. "This investment will help us to strengthen global

defences against outbreaks and pandemics and protect more children from preventable diseases. The United States' partnership has been a key contributor to Gavi's success in immunizing over 1.2 billion children since 2000 and we look forward to renewing this partnership and achieving even greater impact in the years ahead."

.....
.....

Global HIV+

Global HIV response falters as reemergence looms

In 2025, 1.2 million more people became infected with HIV and 570 000 more people died of AIDS-related illnesses as the world fell short of global targets. Without urgent action to meet the 2030 goals, more than 3 million could become infected with HIV by 2030.

RIO DE JANEIRO/GENEVA, 27 July 2026—**A special report released by UNAIDS** for the 26th International AIDS Conference taking place in Rio de Janeiro, Brazil from 27 to 31 July, **shows that reductions to international funding and cuts to HIV prevention and community services are likely to lead to a resurgence of the epidemic.**

Although new HIV infections and AIDS-related deaths are at their lowest levels in more than 30 years, the current HIV response is extremely fragile. Efforts to end AIDS as a public health threat by 2030 are at risk unless global solidarity is restored and inequalities are addressed.

In 2025, 1.2 million people acquired HIV, but progress is uneven. New HIV infections rose in three regions and 21 countries in 2025. Around 9 million of the 41 million people living with HIV were not on treatment and almost half of all children living with HIV did not have access to antiretroviral therapy in 2025. More than half a million people (570 000) died of AIDS-related illnesses in 2025.

Positively seven countries* achieved an almost 80% reduction in new infections since 2010 and 11 countries achieved the 95-95-95** treatment targets showing that progress is possible....

International financing for HIV from multiple countries declined by more than US\$ 1.5 billion, from US\$ 8.8 billion in 2024 to US\$ 7.3 billion in 2025, an 18% reduction and the lowest level in nearly two decades...

...In 2026, 168 countries criminalized sex work, 152 countries criminalized possession of small amounts of drugs, 66 countries criminalized same sex sexual relations, and 14 countries criminalized transgender people.

"You cannot end AIDS while criminalizing people living with and most at risk of HIV," said Ms Byanyima. "When people fear arrest, violence or discrimination, they stay away from HIV services. Human rights are not separate from the HIV response—they are essential to its success." ...

Human rights are under attack and there is a reversal of rights including the sexual and reproductive rights of women and girls and marginalized populations.

For the first time since UNAIDS has been tracking these trends, criminalization of marginalized populations increased. In 2025, Burkina Faso and Niger introduced criminalization of same-sex sexual activity, and Senegal increased penalties for same-sex sexual activity in 2026...

Despite the push back on human rights, in June 2026, 149 Member States adopted a progressive Political Declaration on HIV and AIDS aligned with the UNAIDS Global AIDS Strategy 2026–2031 and its 2030 targets.

The new 2030 targets include 40 million people on life-saving treatment, 20 million with access to antiretroviral-based prevention. The targets also include less than 10% of people living with or at risk of HIV experiencing stigma and discrimination, less than 10% of women and girls and people living with or at risk of HIV experiencing gender inequality and violence, and less than 10% of countries having punitive legal and policy environments that deny or limit access to HIV services.

If fully achieved, the commitments would avert an additional 3.2 million new HIV infections and 1.3 million AIDS-related deaths by 2030.

.....

WHO: Integration, innovation and community leadership key to ending HIV, hepatitis and STIs

27 July 2026

The World Health Organization (WHO) today launched **a new report assessing progress in implementing the Global Health Sector Strategies (GHSS) on HIV, viral hepatitis and sexually transmitted infections (STIs) for 2022–2030.**

Released during the 26th International AIDS Conference (AIDS 2026) and ahead of World Hepatitis Day (28 July), the report highlights significant achievements and persistent challenges in the global response to these epidemics...

The report identifies integration as one of the greatest opportunities to accelerate progress. Countries reporting the strongest results are increasingly delivering services for HIV, viral hepatitis and STIs through primary health care, together with services for tuberculosis, sexual and reproductive health, maternal and child health and noncommunicable diseases.

Eliminating mother-to-child transmission of HIV, syphilis and hepatitis B remains a key priority. Encouragingly, a growing number of countries are applying for WHO validation of elimination, demonstrating that success is within reach when integrated maternal and child health services are strengthened.

Further gains can be achieved by expanding digital health solutions, strengthening interoperable surveillance and health information systems, scaling up multi-disease testing platforms and ensuring equitable access to innovations...

Strengthening community leadership and embedding community-generated data into national monitoring systems can improve accountability, inform programme improvements and help ensure services reach those who are most often left behind.

To support countries in strengthening responses, WHO has released its first consolidated HIV service delivery guidelines bringing together the latest evidence-based recommendations to help countries organize HIV prevention, testing, treatment and long-term care. WHO has also published HIV surveillance guidance, designed to improve routine HIV surveillance systems and enhance the use of national health data for public health action...

.....
.....

Health Financing – Civil Society Voice

[Civil society calls for stronger domestic health financing at the Seventy-ninth World Health Assembly](#)

28 July 2026

Four collective priorities developed through a year-long consultation process were presented to WHO leadership and Member States during a World Health Assembly side event attended by more than 120 participants from governments, civil society, academia and WHO.

Nearly 300 civil society voices have called on WHO leadership and Member States to strengthen domestic health financing, presenting four collective asks at an official side event of the Seventy-ninth World Health Assembly.

The asks, developed through a year-long consultation process convened under the WHO Civil Society Commission in partnership with Save the Children, were presented during “Domestic Leadership in Health Financing: A Dialogue with the WHO Director-General” on 19 May 2026...

Civil society's four asks

On behalf of the Commission and its partners, Nidda Yusuf, Senior Health Financing Advisor at Save the Children, presented four collective asks developed through consultations with civil society organizations worldwide.

The asks called for:

1. **Protection of life-saving essential health services and investment in primary health care**, including a commitment of an additional 1% of GDP to primary health care, explicit protection for sexual and reproductive health, non-communicable disease and mental health services, and equity floors so investment reaches the most vulnerable first.
2. **Stronger domestic health financing**: setting, publishing and tracking country-defined health spending targets, backed by progressive taxation and health taxes, action on illicit financial flows and debt resolution, and improved public financial management so resources reach frontline services.
3. **Institutionalize civil society participation in health governance and decision-making processes**, including formal representation in decision-making bodies and dedicated funding for grassroots and marginalized organizations to participate effectively.
4. **Greater transparency and accountability in health financing data** ahead of the 2027 United Nations High-Level Meeting on Universal Health Coverage, including WHO publication of data disaggregated by gender, disability, geography, age and socioeconomic status, and Member State submission of national health accounts within 12 months of the reference year...

.....
.....
.....

Ebola – Bundibugyo virus disease (BVD) – PHEIC/PHECS

WHO

Disease Outbreak News (DONs)

[01 August 2026 | Ebola disease caused by Bundibugyo virus - Democratic Republic of the Congo](#)

Situation at a glance

The Bundibugyo virus disease (BVD) outbreak in the Democratic Republic of the Congo is intensifying, with sustained transmission and continued increases in reported cases and deaths. Initially confined to the Mongbwalu health zone in Ituri Province, over the last two months, the outbreak has expanded to five provinces (Ituri, North Kivu, South Kivu, Haut-Uélé and Tshopo), now affecting 49 health zones.

The outbreak is now the largest Ebola outbreak ever reported in the Democratic Republic of the Congo. As of 30 July 2026, a total of 3605 confirmed cases, including 1587 deaths, have been reported, corresponding to a crude case fatality ratio (CFR) of 44%. The continued increase in cases, expanding geographic spread, and persistently high mortality underscore the rapidly evolving nature of this public health emergency. During the most recent complete reporting week (epidemiological week 30), the highest weekly number of reported cases (567) and deaths (296) to date were recorded, underscoring the exceptional pace of transmission. The convergence of insecurity, population displacement and mobility, and cross-border movements complicate response operations and increase the risk of further geographical spread. National authorities in the Democratic Republic of the Congo, in collaboration with WHO and partners, continue to implement extensive response measures, however, a substantial scaling up of response activities is needed to get ahead of the outbreak.

A regional preparedness and prioritization framework continues to guide readiness and response activities across the African Region. On 28 July, the Ministry of Health of Uganda declared the end of the BVD outbreak in the country, following 42 days without a new confirmed locally transmitted case after the last confirmed case was discharged from care on 16 June 2026. The most recent imported case was discharged from a treatment centre on 16 July after two negative tests results. Following international guidance WHO will be monitoring the situation for 42 days from this date to ensure no chains of transmission have been missed.

Uganda remains at risk of imported cases and re-introduction of BVD, due to ongoing transmission in neighbouring Democratic Republic of the Congo. WHO reiterates the need to maintain heightened surveillance, preparedness and control measures, particularly in view of continued population movement and the risk of cross-border transmission...

.....
.....

Africa CDC

No new digest content identified.

.....
.....

IPPS

Ebola (Bundibugyo) Day 75 – Tracking Progress on Medical Countermeasures

IPPS - International Pandemic Preparedness Secretariat

July 31, 2026

100 Days Mission clock · Bundibugyo ebolavirus - Day 75

PHEIC declared 18 May 2026...Day 100 falls 25 August 2026

...*Vaccines*

On Day 75, there are no approved vaccines for Bundibugyo virus disease. The Bundibugyo-specific vaccine pipeline has progressed from preclinical development into clinical trials. On 13 July, the University of Oxford launched BD-EBOV-01, the world's first Phase Ia trial of a BDBV-specific vaccine, evaluating ChAdOx1-BDBV (Oxford University/Serum Institute of India) in 50 healthy adults. The first participants were enrolled on 20 July, just ten weeks after the PHEIC declaration, with the first vaccination administered on 24 July. The trial was made possible by manufacturing readiness built on

the existing ChAdOx platform, which allowed the Serum Institute of India to manufacture doses at risk within two weeks (620,000 stockpiled, 4,000 for investigational use).

A second Phase 1 trial, of Moderna's mRNA-LNP candidate, is expected to begin in August. CEPI is funding both programmes, alongside continued development of two rVSV-vectored candidates: rVSV-BDBV-GP (IAVI) and a second candidate developed by Public Health Vaccines based on NIAID research, one of two rVSV candidates BARDA has separately funded Public Health Vaccines to develop. On 12 June, the US Department of State committed \$50 million to CEPI to accelerate BDBV medical countermeasures, with a stated goal of advancing at least two candidates through to emergency authorisation. On 20 July, CEPI published a funding appeal to sustain this programme over the next six to nine months, noting that a significant share of the near-term requirement remains unsecured. On 30 July, CEPI announced a manufacturing partnership with Hilleman Laboratories to produce rVSV-BDBV-GP clinical trial doses, with potential extension to other CEPI-funded rVSV candidates.

CEPI's calls for proposals to advance additional early-stage BDBV candidates toward Phase 1 evaluation, and to generate supporting evidence including epidemiological modelling, closed in June, with selections underway; BARDA's BundiVx Programme, seeking further VSV-platform candidates, closed in July, with outcomes awaited. A CEPI request for information on Phase 1 clinical trial capacity across Africa, published 15 July, found substantial existing capacity across 45 sites in 17 African countries, concentrated particularly in Kenya, South Africa and Uganda...

DAY 75
 EBOLA BUNDIBUGYO
 VIRUS OUTBREAK
 31st July 2026

100 Days Mission BDBV Tools Tracker
Status of vaccines

This overview is not exhaustive.
 See our full disclaimer on our Day 75
 update at: [bit.ly/EbolaBDBV-Day75](#)

Candidate Developer	Platform	Approvals for BDBV	BDBV evidence	Clinical-grade material	Clinical trials relevant to BDBV underway*	Notes
EXISTING LICENSED VACCINES (ZAIRES EBOLAVIRUS)						
Ervebo MSD (rVSV-ZEBOV)	rVSV		 NHP data Partial, non-sterilising protection against BDBV (data generated with research-grade vaccine candidates, not licensed Ervebo product)		N/A WHO SAGE does not recommend for programmatic use in this outbreak	- Existing data shows potential cross-protection; further evidence required to tie to efficacy - NHP model not 100% lethal - Data collected with research-grade rVSV vaccine candidates, not licensed Ervebo product
Zabdeno / Mvabea Janssen (Ad26/MVA)	Ad26 + MVA		 Immunogenicity studies: no meaningful immune response	Status unknown; for experimental use only	N/A WHO SAGE does not recommend for programmatic use in this outbreak	- Limited data on potential cross-protection in human recipients, showing little cross reactivity - Marketing authorisation withdrawn in EU
BDBV-SPECIFIC CANDIDATES (PRECLINICAL)						
rVSV-BDBV-GP IAVI	rVSV		 NHP data 100% protection (pre-exposure) 83% protection (post-exposure)	Not available Development of candidate material at Hilleman Laboratories	0 1 Ph I 2 Ph II 3 Ph III 4 Ph IV	- Most robust preclinical data currently - Small sample size for NHP data - NHP model is not 100% lethal (20-30% survival) - WHO TAG prioritised for near-term evaluation - CEPI-supported
rVSV-BDBV (PHAC) Public Health Vaccines / PHAC	rVSV		 Preclinical data pending	Not available	0 1 Ph I 2 Ph II 3 Ph III 4 Ph IV	- Platform licensed from Public Health Agency of Canada - BARDA-supported
rVSV-BDBV (PHV) Public Health Vaccines / NIAID (Marzi/Feldmann)	rVSV		 NHP data 100% protection (pre-exposure, 3 or 7 days)	Not available	0 1 Ph I 2 Ph II 3 Ph III 4 Ph IV	- BARDA and CEPI supported - NHP model is not 100% lethal (20-30% survival)
ChAdOx1-BDBV Oxford / Serum Institute of India	ChAdOx1		 Preclinical data pending	Dose manufacturing complete Doses supplied for Phase 1 trial SII has manufactured and stockpiled 620,000 doses of the candidate, with 4000 supplied for Phase 1 trial	1 1 Ph I 2 Ph II 3 Ph III 4 Ph IV	- Preclinical data pending, not yet in public domain - CEPI-supported - BD-EBOV-01 Phase 1a trial has initiated enrolment, with first dose administered
mRNA-LNP-BDBV-GP Moderna	mRNA-LNP		 Preclinical data pending	In production	0 1 Ph I 2 Ph II 3 Ph III 4 Ph IV	- mRNA platform offers rapid scale-up potential - Preclinical data limited - Manufacturing route established - CEPI-supported

† See Status of Vaccine Clinical Trials tracker for details on clinical trials underway

DAY 75

EBOLA BUNDIBUGYO VIRUS OUTBREAK

31st July 2026

100 Days Mission BDBV Tools Tracker

Status of vaccines

This overview is not exhaustive. See our full dashboard on our Day 75 update at: bit.ly/EBolaBDBV-Day75

IPPS

Candidate Developer	Platform	Approvals for BDBV	BDBV evidence	Clinical-grade material	Clinical trials relevant to BDBV underway*	Notes
EXISTING LICENSED VACCINES (ZAIRE EBOLAVIRUS)						
Ervebo MSD (rVSV-ZEBOV)	rVSV	✗ Approvals for Zaire ebolavirus only	NHP data Partial non-sterilising protection against BDBV (data generated with research-grade vaccine candidates, not licensed Ervebo product)	✓	N/A WHO SAGE does not recommend for programmatic use in this outbreak	- Existing data shows potential cross-protection; further evidence required to tie to efficacy - NHP model not 100% lethal - Data collected with research-grade rVSV vaccine candidates, not licensed Ervebo product
Zabdeno / Mvabea Jonsson (Ad26/MVA)	Ad26 + MVA	✗ Marketing Authorization for Zaire ebolavirus withdrawn in EU	✗ Immunogenicity studies: no meaningful immune response	Status unknown, for experimental use only	N/A WHO SAGE does not recommend for programmatic use in this outbreak	- Limited data on potential cross-protection in human recipients, showing little cross reactivity - Marketing authorisation withdrawn in EU
BDBV-SPECIFIC CANDIDATES (PRECLINICAL)						
rVSV-BDBV-CP IAVI	rVSV	✗	NHP data 100% protection (pre-exposure) 83% protection (post-exposure)	Not available Development of candidate material at Hilleman Laboratories	0 0 Ph I 0 Ph II 0 Ph III 0 Ph IV	- Most robust preclinical data currently - Small sample size for NHP data - NHP model is not 100% lethal (20-30% survival) - WHO TAC prioritised for near-term evaluation - CEPI-supported
rVSV-BDBV (PHAC) Public Health Vaccines / PHAC	rVSV	✗	L Preclinical data pending	Not available	0 0 Ph I 0 Ph II 0 Ph III 0 Ph IV	- Platform licensed from Public Health Agency of Canada - BARDA-supported
rVSV-BDBV (PHV) Public Health Vaccines / NIAID (Marzi/Feldmann)	rVSV	✗	NHP data 100% protection (pre-exposure, 3 or 7 days)	Not available	0 0 Ph I 0 Ph II 0 Ph III 0 Ph IV	- BARDA and CEPI supported - NHP model is not 100% lethal (20-30% survival)
ChAdOx1-BDBV Oxford / Serum Institute of India	ChAdOx1	✗	L Preclinical data pending	Dose manufacturing complete: Doses supplied for Phase 1 trial SII has manufactured and stockpiled 600,000 doses of the candidate, with 4000 supplied for Phase 1 trial	1 0 Ph I 0 Ph II 0 Ph III 0 Ph IV	- Preclinical data pending, not yet in public domain - CEPI-supported - BD-EBOV-01 Phase 1a trial has initiated enrolment, with first dose administered
mRNA-LNP-BDBV-CP Moderna	mRNA-LNP	✗	L Preclinical data pending	In production	0 0 Ph I 0 Ph II 0 Ph III 0 Ph IV	- mRNA platform offers rapid scale-up potential - Preclinical data limited - Manufacturing route established - CEPI-supported

† See status of Vaccine Clinical Trials tracker for details on clinical trials underway

.....
.....
.....

Polio – PHEIC

[Polio this week](#) [29 July 2026]

Headlines [Selected]

:: **What the latest routine immunization coverage estimates mean for eradication**

The newly-released 2025 WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) show a mixed picture for polio...

:: **Women football stars team up to kick polio out of Africa**

As the Women's Africa Cup of Nations kicks off, some of the continent's biggest football stars are stepping up to end polio. The "Kick Out Polio" campaign features 11 women footballers from Côte d'Ivoire, Cameroon and Nigeria...[Read](#) how women athletes are speaking up...

:: **Zambia targets 3.9 million children in latest polio vaccination campaign**

Following poliovirus detection earlier this year, Zambia launched the third round of its polio vaccination campaign this month...

Summary of new polioviruses this week:

- :: Pakistan: two WPV1-positive environmental samples
- :: Democratic Republic of the Congo: four cVDPV2 cases
- :: Lao People's Democratic Republic: one cVDPV1 case
- :: South Sudan: one cVDPV1 case

.....
.....

Contents [click to move among sections]

- :: [Milestones, Perspectives](#)
- :: [WHO](#)
- :: [U.S. Immunization and Public Health Governance/Policy/Funding](#)
- :: [Organization Announcements](#)
- :: [Journal Watch](#)
- :: [Pre-Print Servers](#)
- :: [Think Tanks](#)
- :: [Public Consultations/Call for Inputs/Call for Papers](#)

.....
.....

WHO & Regional Offices [01 Aug 2026]

<https://www.who.int/news>

Selected News/Announcements/Statements

31 July 2026 *Statement*

[**Countries urged to strengthen breastfeeding support and health systems to give every child a healthy start in life**](#)

30 July 2026 *Medical product alert*

[**Statement from the Joint Meeting of the Advisory Committee on Safety of Medicinal Products \(ACSoMP\) and the Global Advisory Committee on Vaccine Safety \(GACVS\) on the safe and appropriate use of GLP-1 receptor agonists**](#)

29 July 2026 *Departmental update*

[WHO launches first global framework to help regulators advance greener pharmaceuticals](#)

29 July 2026 *Departmental update*

[WHO updates treatment guidelines on visceral and post-kala-azar dermal leishmaniasis](#)

28 July 2026 *Departmental update*

[Civil society calls for stronger domestic health financing at the Seventy-ninth World Health Assembly](#)

28 July 2026 *Departmental update*

[Civil society pushes for action on health financing](#)

28 July 2026 *Departmental update*

[Health financing under pressure as civil society calls for urgent action](#)

28 July 2026 *Departmental update*

[WHO champions self-care for HIV, TB, hepatitis, sexually transmitted infections and mental health](#)

27 July 2026 *News release*

[WHO: Integration, innovation and community leadership key to ending HIV, hepatitis and STIs](#)

27 July 2026 *Departmental update*

[BRICS elevates traditional medicine with landmark declaration and new expert working group](#)

:::::::

WHO Vaccines and Immunization [IVB]

https://www.who.int/health-topics/vaccines-and-immunization#tab=tab_1

News

No new digest content identified.

:::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 31 July 2026 | *News releases*

[WHO and Pandemic Fund Support Ethiopia to Strengthen Public Health Emergency Workforce Capacity](#)

:: 30 July 2026 | *News releases*

[Ghana reviews one year of pandemic fund implementation](#)

WHO Region of the Americas PAHO

:: 31 Jul 2026

[PAHO calls for stronger safeguards against digital marketing that undermines breastfeeding](#)

During World Breastfeeding Week, PAHO warns that increasingly sophisticated digital marketing of breast-milk substitutes is influencing infant feeding decisions and calls for stronger regulation and monitoring of online advertising. Washington, D.C., 31 July 2026 (PAHO) – Ahead of World Breastfeeding Week (1-7 August), the Pan American Health...

:: 31 Jul 2026

Venezuela strengthens disease diagnostic capacity after earthquakes with PAHO/WHO support

Caracas, Venezuela, July 31, 2026 – The Pan American Health Organization/World Health Organization (PAHO/WHO) has delivered molecular diagnostic supplies to Venezuela to strengthen the diagnostic capacity of the country's National Laboratory Network following the June 24 earthquakes, with the aim of preventing disease outbreaks and protecting the...

:: 27 Jul 2026

AIDS 2026: The Americas have the tools to eliminate HIV, but gaps in access and coverage remain, says PAHO

PAHO Director calls for expanded access to innovations such as oral and injectable PrEP, rapid testing, and HIV self-testing, while strengthening early diagnosis and timely treatment initiation to advance HIV elimination. Rio de Janeiro, Brazil, 27 July 2026 (PAHO) – The Region of the Americas has more tools than ever before to prevent, diagnose,...

:: 27 Jul 2026

New collaboration between PAHO and AIDS Healthcare Foundation to expand early HIV diagnosis in Latin America and the Caribbean

Rio de Janeiro, Brazil, 27 July 2026 (PAHO) – The Pan American Health Organization (PAHO) and AIDS Healthcare Foundation (AHF) will collaborate to expand early HIV diagnosis in Latin America and the Caribbean, with the aim of improving access to testing, facilitating timely linkage to care, and helping reduce preventable AIDS-related deaths....

:: 24 Jul 2026

Haiti strengthens rabies response with donation of 10,000 vaccine doses from Brazil

Port-au-Prince, Haiti, 24 July 2026 (PAHO) – Haiti's Ministry of Public Health and Population (MSPP) has received a donation of 10,000 human rabies vaccine doses from the Government of Brazil, delivered through the Pan American Health Organization (PAHO), to help strengthen the country's response to a disease that remains a public health threat....

WHO South-East Asia Region SEARO

:: 28 July 2026 *Statement*

World Hepatitis Day

WHO European Region EURO

:: 28 July 2026 *News release*

World Hepatitis Day 2026: progress made against hepatitis in Europe, but millions still miss out on diagnosis and treatment

WHO Eastern Mediterranean Region EMRO

:: WHO Regional Director reaffirms support as Pakistan intensifies "critical" efforts to interrupt polio transmission over the next 6 months

27 July 2026

WHO Regional Director for the Eastern Mediterranean Dr Hanan Balkhy met Pakistan's leadership as part of a high-level mission of the Polio Oversight Board to discuss joint efforts and seize the opportunity to further confine wild poliovirus by enhancing vaccination in high-risk areas, surveillance, routine immunization and cross-border cooperation.

WHO Western Pacific Region

No new digest content identified.

.....

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

No new digest content identified.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health

1 August 2026 | Ebola disease caused by Bundibugyo virus - Democratic Republic of the Congo

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Volume 101 Issue 29 Epidemiological Week 29 (13 July – 19 July 2026)

<https://iris.who.int/server/api/core/bitstreams/bae50897-d67b-4cd0-a9f0-792fc346ce00/content>

:: Highlighted signals and events

:: Dengue Global Update

:: Summary of the 41st Meeting of the International Task Force for Disease Eradication: Elimination of Trachoma as a Public Health Problem

[Reviewed earlier]

.....

New WHO Publications

<https://www.who.int/publications>

Selected

31 July 2026

WHO position paper on COVID-19 vaccines - July 2026

Overview

This WHO Position Paper updates WHO recommendations on the use of COVID-19 vaccines in the context of sustained SARS-CoV-2 circulation, high levels of population immunity, and the availability of variant-adapted vaccines.

Developed following recommendations by the Strategic Advisory Group of Experts (SAGE) on Immunization, it summarizes current evidence on COVID-19 epidemiology, populations at increased risk of severe disease, vaccine characteristics, immunogenicity, effectiveness, safety, and programme implementation.

The paper presents WHO's current policy recommendations for the use of COVID-19 vaccines across different population groups and settings, addressing vaccine schedules, product choice, coadministration, implementation considerations, and monitoring.


It also identifies evidence gaps and research priorities and provides guidance to support national immunization policies and vaccination programmes as countries integrate COVID-19 vaccination into long-term disease management strategies.

31 July 2026

Attacks on health care Dashboard 2024

Overview

Health care is under attack. The sanctity of health care, the right to health, and International Humanitarian Law are threatened. Such attacks deprive people of urgently needed care, endanger health care providers, and undermine health systems. This Dashboard reports the number of attacks, deaths, injuries and countries and territories affected within one year.



31 July 2026

[Routine health information system and health facility data for neglected tropical diseases: Taenia solium...](#)

28 July 2026

[WHO guidelines on leishmaniases: treatment of visceral leishmaniasis and post-kala-azar dermal leishmaniasis...](#)

27 July 2026

[Global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, 2022–2030:...](#)

27 July 2026

[Consolidated guidance for strengthening national routine surveillance systems: updated HIV case definitions,...](#)

.....
.....
.....

Africa

Africa CDC [01 Aug 2026]

<https://africacdc.org/>

News & Updates [Selected]

Africa Advances a New Model for Global Health Innovation

30 July 2026

MSD partnerships in Kenya, South Africa and Uganda link clinical research, manufacturing and future access.

Addis Ababa, Ethiopia, 30 July 2026 – The Africa Centres for Disease Control and Prevention (Africa CDC) welcomes MSD's voluntary licensing agreements with three African pharmaceutical manufacturers for an investigational once-monthly oral HIV pre-exposure prophylaxis candidate known as MK-8527...

Press Releases

From Prevention to Sovereignty: Accelerating Viral Hepatitis Elimination in Africa

28 July 2026

...Call to Action

Investing in viral hepatitis elimination therefore strengthens far more than health outcomes. It protects workforce productivity, reduces long-term health expenditure, strengthens economic resilience and advances sustainable development. Accelerating elimination requires the very capabilities that define AHSS: resilient primary health care, integrated surveillance and laboratory networks, predictable domestic financing, digital transformation, stronger regional cooperation, local manufacturing and pooled procurement mechanisms.

Therefore, as we observe World Hepatitis Day, we urge our Member States and partners to enhance our response efforts in these five critical areas:

1. Increase domestic financing and innovative funding mechanisms to expand hepatitis prevention, testing, and treatment while reducing reliance on external aid. African governments should explore new sources of domestic and blended financing, including solidarity levies, health security bonds, diaspora bonds, sin taxes, and catalytic private-sector investment, to complement public financing.
2. Strengthen local manufacturing and pooled procurement of vaccines, diagnostics, and antiviral medicines to improve access, affordability, and supply security.
3. Integrate hepatitis services into primary health care and digital health systems, ensuring that every newborn receives timely hepatitis B vaccination and every diagnosed person is linked to care and treatment.
4. Deepen regional cooperation and partnerships to share expertise, scale proven interventions, and sustain momentum toward the 2030 elimination targets.
5. Promote public awareness and community engagement to reduce stigma, increase demand for testing, and improve vaccine uptake. Civil society and community organizations should be engaged as key partners in elimination efforts.

Press Releases

Africa CDC and PSI Partner to Expand Innovative Approaches for Immunisation and Primary Healthcare Access in Africa

28 July 2026

Addis Ababa, Ethiopia, 28 July 2026 – A new partnership agreement between the Africa Centres for Disease Control and Prevention (Africa CDC) and Population Services International (PSI) will strengthen efforts to expand access to immunisation and integrated primary healthcare services across Africa...

Through the Memorandum of Understanding (MoU) signed by Africa CDC Director General Dr Jean Kaseya and PSI President Michael Holscher, the two organisations will collaborate on innovative approaches to preventive healthcare, including pharmacy-based immunisation community delivery models, stronger public-private partnerships, health workforce integration, evidence generation and knowledge exchange...

African Medicines Agency [01 Aug 2026]

<https://au-ama.africa/news-events/>

Latest News & Events
No new digest content identified.

.....
.....

China – CDC+

National Health Commission of the People's Republic of China [01 Aug 2026]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [01 Aug 2026]

<http://english.nmpa.gov.cn/>

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (8)

<https://weekly.chinacdc.cn/article/current>

2026 Vol. 8 No. 31 [PDF](#)

Healthy China

[Interpretation of China's Action Plan for Viral Hepatitis Prevention and Care \(2025–2030\)](#)

Jing Han, Jian Li, Zhongfu Liu, Jun Yan, Weijuan Yan

Preplanned Studies

[Global Cross-Border Migration and Secondary Transmission Patterns of Lassa Fever — Global, 1969–2025](#)

Zekun Wang, Na Zeng

.....
.....

Europe

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

[As sustained heatwaves increase the risk of infectious diseases across Europe, ECDC scales up action and calls for cooperation](#)

29 July 2026

[World Hepatitis Day 2026: Ensuring that life-saving interventions are accessible to everyone who needs them is a common challenge](#)

28 July 2026

Publications

Surveillance and monitoring

[Communicable disease threats report, 27 - 31 July 2026, week 31](#)

31 July 2026

Surveillance and monitoring

Progress in the prevention of vertical transmission of viral hepatitis B in the EU/EEA

28 July 2026

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

New leadership team appointments

Appointments made as Ivo Claassen retires

30 July 2026

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2026

Twelve new medicines recommended for approval; another eight medicines recommended for extension of their therapeutic indications

24 July 2026

.....
.....

India

National Centre for Disease Control

Directorate General of Health Services, Ministry of Health & Family Welfare

Announcements

No new digest content identified.

.....
.....
.....

U.S. Immunization and Public Health Governance/Policy/Funding

Given the continuing extraordinary situation in the U.S., we have established a separate section of the digest to capture and organize key content. Please note that we will selectively include external analysis and comment, either boxing or indenting this content under the relevant organization/action. We recognize that despite the volume of content in this section, this summary is indicative and not exhaustive

Executive Branch - White House, State, HHS, FDA, CDC+ White House

Presidential Actions – Executive Orders; Memoranda; Proclamations

No new digest content identified.

Department of State

Press Releases - Selected

Media Note

U.S. Department of State and U.S. Department of Health and Human Services on Strengthening Vaccine Safety, Accountability, and American Leadership in Global Health

July 29, 2026

[2025-26 Gavi funds released]

HHS

Press Room - Selected

Joint Statement on Strengthening Vaccine Safety, Accountability, and American Leadership in Global Health

July 29, 2026 *Press Release*
[2025-26 Gavi funds released]

Joint Statement on the United States Government Policy for Stopping High-Risk Life Sciences Research

July 28, 2026 *Press Release*

...The release of the [United States Government Policy for Stopping High-Risk Life Sciences Research \[PDF, 1.50 MB\]](#) fulfills President Trump's commitment to ensure that federally supported life sciences research serves the interests of the American people. This policy stops dangerous gain-of-function research that has the potential to threaten lives, disrupt communities, strain public health systems, and undermine America's economic and national security if not properly restricted and controlled...

Trump Administration Releases New Government-Wide Policy to End Dangerous High-Risk Research

WASHINGTON — JULY 28, 2026 — The U.S. Department of Health and Human Services (HHS) today applauds the release of the Trump Administration's new United States Government Policy for Stopping High-Risk Life Sciences Research. This comprehensive framework prohibits federally supported dangerous gain-of-function (DGO) research while establishing stronger oversight for life sciences research that could pose significant risks to public health, biosecurity, or national security. The policy fulfills President Trump's [Executive Order](#) aimed at improving the safety and security of biological research, and it ensures that taxpayer-funded research advances scientific discovery and medical innovation without exposing Americans to biological risks...

NIH [to 01 Aug 2026]

News Releases

NIH selects Dr. Courtney Aclin as director of the National Institute of Nursing Research

July 24, 2026 — Dr. Aclin is expected to begin her permanent role as the NINR director on July 26, 2026

FDA

Press Announcements

No new digest content identified.

FDA CBER

What's New for Biologics

7/31/2026 [July 31, 2026 Approval Letter - Alphanate](#)

7/31/2026 [July 30, 2026 Approval Letter - ADACEL](#)

07/31/2026 [Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts; Draft Guidance for Industry](#)

07/30/2026 [SOPP 8401: Administrative Processing of Original Biologics License Applications \(BLA\) and New Drug Applications \(NDA\)](#)

07/29/2026 [July 29, 2026 Approval Letter - EZPLAZ](#)

07/28/2026 [July 27, 2026 Approval Letter - AREXVY](#)

07/27/2026 [Cancer Clinical Trial Eligibility Criteria: Laboratory Values; Guidance for Industry, IRBs, and Clinical Investigators](#)

07/27/2026 [Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications; Guidance for Industry, IRBs, and Clinical Investigators](#)

07/27/2026 [Cancer Clinical Trial Eligibility Criteria: Performance Status; Guidance for Industry, IRBs, and Clinical Investigators](#)

FDA VRBPAC [Vaccines and Related Biological Products Advisory Committee]

[Advisory Committee Calendar](#)

No future meeting dates posted.

FDA Pediatric Advisory Committee Meeting

[Advisory Committee Calendar](#)

No future meeting dates posted.

CDC

<http://www.cdc.gov/media/index.html>

Latest News - Selected

No new digest content identified.

CDC – Immunization Safety Office (ISO)

<https://www.cdc.gov/vaccine-safety-systems/about/cdc-monitoring-program.html>

No new digest content identified [last updated August 7, 2024]

ACIP

2026 Meetings Schedule

- March 18-19 (Due to ongoing litigation, this meeting is cancelled)
- June 24-26 (Due to ongoing litigation, this meeting is cancelled)
- October 21-23

National Vaccine Advisory Committee (NVAC)

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)

<https://www.hrsa.gov/advisory-committees/vaccines/meetings>

Next ACCV meetings – TBD

Recharter for the Advisory Commission on Childhood Vaccines

A Notice by the Health Resources and Services Administration on 07/21/2026

SUMMARY:

In accordance with the Federal Advisory Committee Act (FACA), the Department of Health and Human Services is hereby giving notice that the Advisory Commission on Childhood Vaccines (ACCV) has been rechartered. The effective date of the renewed charter is July 21, 2026. ... A copy of the ACCV charter is available on the ACCV website at

<https://www.hrsa.gov/advisory-committees/vaccines/index.html>.

MMWR Weekly

<https://www.cdc.gov/mmwr/index2026.html>

July 30, 2026 / No. 29

[PDF of this issue](#)

:: [West Nile Virus and Other Nationally Notifiable Arboviral Diseases — United States, 2024](#)

:::::::

National Science Foundation/NSF

News

No new digest content identified.

.....

U.S. Congress

House

No new digest content identified.

Senate

Senate Health, Education, Labor and Pensions committee

Committee approvals:

:: 07/30/2026

Erica Schwartz, of Florida, to be Director of the Centers for Disease Control and Prevention, vice Susan Monarez.

Nomination Number: PN932-119 Received Date: 04/21/2026

Last Action: Placed on Senate Executive Calendar. Calendar No. 910...

:: 07/30/2026

Sean Kaufman, of Georgia, to be Assistant Secretary for Preparedness and Response, Department of Health and Human Services, vice Dawn Myers O'Connell, resigned.

Nomination Number: PN937-3-119 Received Date: 04/27/2026

Last Action: Placed on Senate Executive Calendar. Calendar No. 9

.....

Supreme Court, Federal & Appellate Courts

O'Neill Institute – Health Care Litigation Tracker [Georgetown University]

<https://litigationtracker.law.georgetown.edu/>

No new digest content identified.

.....

.....

.....

U.S. Medical, Scientific, Professional Societies; Health Organizations

This inventory is evolving and may not capture all instances of relevant comment and analysis.

American Academy of Family Physicians (AAFP)

<https://www.aafp.org/news/media-center.html>

(Accessed 01 Aug 2026)

No new digest content identified.

American Academy of Pediatrics (AAP)

<https://www.aap.org/en/news-room/news-releases-from-the-aap/>

(Accessed 01 Aug 2026)

News

No new digest content identified.

American College of Physicians (ACP)

<https://www.acponline.org/more-acp-news>

(Accessed 01 Aug 2026)

No new digest content identified.

America's Health Insurance Plans (AHIP)

<https://www.ahip.org/news>

(Accessed 01 Aug 2026)

News

No new digest content identified.

American Geriatrics Society (AGS)

<https://www.americangeriatrics.org/media-center>

(Accessed 01 Aug 2026)

Recent Press Releases

No new digest content identified.

American Medical Association (AMA)

<https://www.ama-assn.org/press-center>

(Accessed 01 Aug 2026)

Press Releases

No new digest content identified.

American Osteopathic Association (AOA)

<https://osteopathic.org/news/>

(Accessed 01 Aug 2026)

Latest News

No new digest content identified.

American Public Health Association (APHA)

<https://www.apha.org/news-and-media/news-releases?sortFieldName=ItemDate&sortDisplayName=Newest&sortMode=desc>

(Accessed 01 Aug 2026)

No new digest content identified.

Infectious Diseases Society of America (IDSA)

<https://www.idsociety.org/>

(Accessed 01 Aug 2026)

No new digest content identified.

National Foundation for Infectious Diseases (NFID)

<https://www.nfid.org/news-updates/>

(Accessed 01 Aug 2026)

News and Updates

No new digest content identified.

National Medical Association (NMA)

<https://nmanet.org/blog/>

(Accessed 01 Aug 2026)

Latest News

No new digest content identified.

Pediatric Infectious Diseases Society (PIDS)

<https://pids.org/news-announcements/>

(Accessed 01 Aug 2026)

News & Announcements

No new digest content identified.

Society for Healthcare Epidemiology of America (SHEA)

<https://shea-online.org/news/>

(Accessed 01 Aug 2026)

No new digest content identified.

Society for Maternal-Fetal Medicine (SMFM)

<https://www.smfm.org/>

(Accessed 01 Aug 2026)

News

No new digest content identified.

.....
.....

Civil Society – Individuals, Organizations, Institutions [Selected]

.....

Kaiser Family Foundation/KFF [01 Aug 2026]

https://www.kff.org/search/?post_type=press-release

Research, Analysis

Donor Government Funding for HIV Dropped by \$2.1 Billion in 2025 Due to Declines in U.S. Disbursements, Marking the Largest Annual Decrease Since HIV Response Scale Up Began

Jul 29, 2026 *Quick Insights*

Donor government funding to combat HIV in low- and middle-income countries fell by \$2.1 billion in 2025, a 25% decrease from the previous year. The 2025 decrease was driven by a decline in U.S. disbursements following the administration's substantial cuts in global health funding, programs, and personnel. Despite this decline, the U.S. remains the largest donor to HIV in the world.

State Requirements for Private Insurance Coverage of Vaccines

Jul 29, 2026 *State Health Facts Indicator*

Most Aren't Confident in the CDC and FDA to Make Recommendations About Childhood Vaccine Schedules

Jul 28, 2026 *Quick Insights*

Most adults (56%) say they have “little” to “no confidence” in federal health agencies like the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) to make recommendations about childhood vaccine schedules.

Comparing U.S. Ebola Outbreak Response Capabilities and Practices Over Time

Jul 28, 2026 *Issue Brief*

This brief compares the U.S. response to the current Ebola outbreak in DRC with U.S. responses to prior Ebola outbreaks across a variety of characteristics. It finds the US is on par or even faster with response funding, but the restructuring of the US response mechanisms and leadership (such as eliminating USAID) since 2025 have changed the organizational approach with unknown consequences, and how the US is engaging with international partners is different now.

KFF Health Tracking Poll: Ebola & Pandemic Preparedness

Jul 28, 2026 *Poll Finding*

Much of the public has yet to form an opinion on the U.S. government’s response to the Ebola outbreak in the Democratic Republic of the Congo, this poll finds. Four in ten adults say the U.S. is less prepared for a pandemic now than it was in 2020.

Donor Government Funding for HIV in Low- and Middle-Income Countries in 2025

Jul 27, 2026 *Report*

This report provides an analysis of donor government funding to address the HIV response in low- and middle-income countries in 2025, the latest year available, as well as trends over time. It includes both bilateral funding from donors and their multilateral contributions to the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), UNITAID, and Joint United Nations Programme on HIV/AIDS (UNAIDS).

Donor Government Funding for HIV Drops by \$2.1 Billion in 2025 Due to Declines in Funding from the United States, Marking Largest Annual Decrease Since Scale-up for the HIV Response Began

Jul 27, 2026 *News Release*

Donor government funding to combat HIV in low- and middle-income countries fell by \$2.1 billion in 2025, a 25% decrease from the previous year, according to a new report by KFF and the Joint United Nations Programme on HIV/AIDS (UNAIDS). Total disbursements dropped to \$6.2 billion in 2025, down from \$8.3 billion in 2024, marking the largest single-year decline since donor funding scale-up began and the lowest funding level since 2007, the report finds. The...

.....

Vaccine Integrity Project – CIDRAP [to 01 Aug 2026]

<https://www.cidrap.umn.edu/vaccine-integrity-project>

Announcements, Viewpoints

No new digest content identified.

.....

Center for Vaccine Ethics & Policy - GE2P2 Global Foundation [to 01 Aug 2026]

<https://centerforvaccineethicsandpolicy.net/>

No new digest content identified.

.....

Paul Offit, MD – *Beyond the Noise*

Substack: <https://pauloffit.substack.com/>
No new digest content identified.

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)
:: [*WHO*](#)
:: [*Organization Announcements*](#)
:: [*Journal Watch*](#)
:: [*Pre-Print Servers*](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [01 Aug 2026]
<https://alleninstitute.org/news-press/>
News
No new digest content identified.

Gates Foundation [01 Aug 2026]
<https://www.gatesfoundation.org/ideas/media-center>
Press Releases & Statements
No new digest content identified.

CARB-X [01 Aug 2026]
<https://carb-x.org/>
News
No new digest content identified..

Chan Zuckerberg Initiative [01 Aug 2026]
<https://chanzuckerberg.com/newsroom/>
Newsroom
No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [01 Aug 2026]
<http://cepi.net/>
News

[**Hilleman Laboratories to develop and produce CEPI-backed Bundibugyo ebolavirus vaccine doses for clinical trials**](#)

29 Jul 2026

Explainer

[**CEPI 3.0 explained: Networks**](#)

29 Jul 2026

Biospecimen Sourcing Initiative

Biospecimen Sourcing Initiative Call for Technical Partners Vi

The objective of this Call for Proposals is to identify and select technical partners for the Biospecimen Sourcing Initiative.

DEADLINE EXTENSION: Please note that the application submission deadline for this Call has been extended to 12 August 2026. See below for more details.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 01 Aug 2026]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [01 Aug 2026]

<https://www.darpa.mil/news>

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases Initiative [01 Aug 2026]

<https://dndi.org/press/press-releases/>

Press Releases

Press releases 29 Jul 2026

WHO recommends new, better and safer treatment regimens for leishmaniasis

Press releases 27 Jul 2026

DNDi leadership to change in 2027

After four years, Dr Luis Pizarro will be stepping down from his role as DNDi's Executive Director to take on a new position as Executive Director at Unitaaid at the end of 2026...DNDi's Board will now actively engage in a search process to identify a new Executive Director who will continue to champion DNDi's mission to bring best science to the most neglected.

Duke Global Health Innovation Center [01 Aug 2026]

<https://dukeghic.org/>

News

ALIGN Case Studies – Full Series

July 15, 2026

The series is produced by the ALIGN Consortium as part of our shared learning agenda. Each case study—featuring Thailand, the Netherlands, and Ghana—examines how a particular country has nav...

EDCTP [01 Aug 2026]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

31 July 2026

EDCTP2 demonstrates impact on health, policy and research capacity

The EDCTP Association has published its Annual Report 2025, presenting a decade of progress in EDCTP2 advancing medical interventions, strengthening research capacity and building equitable partnerships across sub-Saharan Africa.

30 July 2026

EMPIRICAL study offers new evidence for treating severe pneumonia in infants living with HIV

Emory Vaccine Center [01 Aug 2026]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [01 Aug 2026]

<http://www.euvaccine.eu/>

News

World Hepatitis Day 2026: "Hepatitis: Let's Break It Down"

Every year on 28 July, World Hepatitis Day raises awareness of viral hepatitis and the urgent need to prevent, diagnose and treat

Fondation Merieux [01 Aug 2026]

<http://www.fondation-merieux.org/>

Actualités

No new digest content identified.

Gates Medical Research Institute [01 Aug 2026]

<https://www.gatesmri.org/news>

News: Articles and Publications

Qualification of a high-throughput luminescence-based serum bactericidal activity assay to assess the functionality of human sera against five Shigella serotypes

August 13, 2026 *Vaccine*

The role of interferon-gamma release assays in tuberculosis vaccine trials: strengths, limitations, and implications beyond trial design

August 13, 2026 *Vaccine*

Associations Between QuantiFERON-TB Gold Plus IFN γ Concentrations and Progression to Symptomatic Tuberculosis in Global High-Burden TB Settings

July 24, 2026 *Open Forum Infectious Diseases*

Gavi [to 01 Aug 2026]

<https://www.gavi.org/>

News Releases, VaccinesWork

30 July 2026

Gavi welcomes United States government commitment to unlock funding for fiscal years 2025 and 2026

GE2P2 Global Foundation [01 Aug 2026]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements/Digests

:: **Vaccines and Global Health: The Week in Review** - Current edition

:: **Public Consultations Watch :: Global Calls for Input/Public Comment – 29 July 2026**

GHIT Fund [01 Aug 2026]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 01 Aug 2026]

<https://www.theglobalfund.org/en/news/>

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [01 Aug 2026]

<https://www.glopid-r.org/>

News & Event

No new digest content identified.

Hilleman Laboratories [01 Aug 2026]

<http://www.hilleman-labs.org/>

News & Insights

Press Release

Hilleman Laboratories to develop and produce CEPI-backed Bundibugyo ebolavirus vaccine doses for clinical trials

OSLO/SINGAPORE, 30 July 2026 — The Coalition for Epidemic Preparedness Innovations (CEPI) is collaborating with Hilleman Laboratories, a Singapore-based joint venture of biopharmaceutical company MSD and charitable foundation Wellcome, to advance the development and manufacturing of Bundibugyo ebolavirus vaccine candidate doses for clinical trials using the recombinant vesicular stomatitis virus (rVSV) platform.

With up to US\$8.5 million in CEPI funding, Hilleman Laboratories will advance development and manufacture clinical supply of the investigational vaccine at the organisation's vaccine production facility as scientists ramp up efforts to respond to one of the largest Ebola outbreaks on record, which is predominantly affecting the Democratic Republic of the Congo.

Assuming early phase trials succeed, the partners are committed to swiftly transferring the vaccine technology to a large-scale vaccine manufacturer to produce additional doses, as needed, for later-stage trials. A further aim of the technology transfer would be to ensure rapid, affordable supply of doses in outbreak-affected countries and low- and middle-income settings if the vaccine is authorised for use...

HHMI - Howard Hughes Medical Institute [01 Aug 2026]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [01 Aug 2026]

<https://www.humanimmunomeproject.org/>

News

No new digest content identified.

IAVI [01 Aug 2026]

<https://www.iavi.org/>

Press Releases, Features

In The News

[**New study supports testing of Merck's Ebola vaccine in DRC outbreak**](#)

STAT July 23, 2026

INSERM [01 Aug 2026]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 01 Aug 2026]

<https://www.ich.org/page/public-consultations>

News/Pubs/Press Releases [Selected]

30 July 2026

[**Updated support package published for ICH M8: Electronic Common Technical Document \(eCTD\)**](#)

The ICH M8: Electronic Common Technical Document (eCTD) Implementation Working Group has issued updates to multiple support materials for eCTD v4.0 which are available for download: the Implementation Guide Package, the Controlled Vocabulary Package and the Q&A document.

ICRC [to 01 Aug 2026]

<https://www.icrc.org/en/news>

Latest press releases and statements

No new digest content identified.

IFFIm [01 Aug 2026]

<http://www.iffim.org/>

Press Releases/Announcements

Vaccine impact: rubella birth defects drop by almost 75% since 2012

30 Jul 2026

New modelling by the US CDC shows the impact that increasing access to the rubella vaccine has had on cases of congenital rubella syndrome.

IFRC [to 01 Aug 2026]

<http://media.ifrc.org/ifrc/news/press-releases/>

No new digest content identified.

IPPS - International Pandemic Preparedness Secretariat [01 Aug 2026]

<https://ippsecretariat.org/news/>

News

Ebola (Bundibugyo) Day 75 – Tracking Progress on Medical Countermeasures

July 31, 2026

100 Days Mission clock • Bundibugyo ebolavirus - Day 75

PHEIC declared 18 May 2026 Day 100 falls 25 August 2026

The 100 Days Mission (100DM) clock for Bundibugyo ebolavirus (BDBV) started on 18 May 2026, following WHO's declaration of the outbreak as a public health emergency of international concern (PHEIC). Africa CDC declared a Public Health Emergency of Continental Security (PHECS) the following day.

Institut Pasteur [01 Aug 2026]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

InterAcademy Partnership (IAP)

<https://www.interacademies.org/news/press-releases>

News

Wed, 29 July 2026

UNESCO Opens Call for Remote Access to AI Infrastructure

UNESCO and the Computing and Artificial Intelligence Laboratory at the Brazilian Center for Physics Research (AI-Lab/CBPF) have launched a new international call offering researchers remote access to advanced artificial intelligence (AI) and high-performance computing (HPC) infrastructure. The initiative aims to expand equitable access to cutting-edge research facilities and strengthen scientific capacity in regions where such resources remain limited.

The opportunity is open to Master's and PhD students, postdoctoral researchers and junior faculty members from Africa, Latin America and the Caribbean, Ukraine and Small Island Developing States (SIDS). Selected participants will gain access to AI computing resources, technical training and mentoring, supporting collaborative research in areas such as AI, data science and computational modelling. Training and remote access are expected to begin in October 2026.

The programme forms part of UNESCO's Remote Access to Lab Equipment (UNESRALE) initiative, which works with international partners to improve access to advanced scientific infrastructure and promote more inclusive participation in research worldwide.

Applications close on 31 August 2026. Researchers interested in applying can find further information on the [UNESCO website](#).

ISC / International Science Council [to 01 Aug 2026]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

blog

29 July 2026 - 17 min read

[The hidden cost of scientific isolation: Lessons from Sudan's research system](#)

news

28 July 2026 - 10 min read

[Research needs a shared standard for AI disclosure](#)

Research integrity now depends on a shared global standard for how scientists disclose their use of AI.

blog

28 July 2026 - 13 min read

[Can science shape its own future?](#)

Science play a central role in assisting the global public good, societal wellbeing and planetary health. What will its future look like?

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News, Resources

[Defending the Foundations of Biomedical Science: IUIS Responds to Proposed OMB Rule](#)

July 30, 2026

A proposed rule from the White House Office of Management and Budget (OMB) threatens to reshape how US biomedical research is funded — replacing merit-based peer review with non-scientific approval criteria, restricting international conference participation, limiting professional society memberships, and curtailing cross-border scientific collaboration.

As the global union representing nearly 30,000 immunologists across 84 member societies, IUIS has submitted formal comments to OMB opposing these changes. We believe independent, expert-driven peer review and open international scientific exchange are essential to continued progress in immunology and biomedical science — and that this rule, if implemented, would weaken both.

[Read the Full Comments](#)

IVAC [01 Aug 2026]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

July 28, 2026

[Shaun Truelove, Andrea Carcelen Named as New IVAC Leadership](#)

Congratulations to Shaun Truelove, PhD, MPH, who will be the next Executive Director of the International Vaccine Access Center, and to Andrea Carcelen, PhD, MPH, who will serve as Deputy Director. As of August 1, 2026, Drs. Truelove and Carcelen will take over IVAC's leadership from Dr. William Moss, who served as the Center's Executive Director for nearly eight years.

July 27, 2026

[Latest Global Immunization Coverage Estimates Illustrate Gaps in Vaccine Access](#)

IVI [01 Aug 2026]

<http://www.ivi.int/>

IVI News & Announcements

Uncovering the hidden burden of hepatitis E in maternal health

28 July 2026

Through an International Vaccine Institute (IVI) project in Burkina Faso, field study coordinators Lady Rosny Wandji Nana and Enoch Cakpo are helping to generate critical evidence on the hepatitis E virus (HEV) and its impact on pregnant women—a largely overlooked infection that can pose serious health risks for mothers and babies

Johns Hopkins Center for Health Security [01 Aug 2026]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

Robert Wood Johnson Foundation [to 01 Aug 2026]

<https://www.rwjf.org/en/about-rwjf/newsroom.html>

Latest News and Highlights

No new digest content identified.

MSF/Médecins Sans Frontières [to 01 Aug 2026]

<http://www.msf.org/>

Latest [Selected Announcements]

Chad

One in five pregnant women in eastern Chad are malnourished amid funding cuts

Press Release 30 Jul 2026

Iran

MSF expands care for excluded communities in Iran as crisis continues

Project Update 28 Jul 2026

National Academy of Medicine - USA [to 01 Aug 2026]

<https://nam.edu/programs/>

News, Stories, Insights

Jul 27, 2026 News

NAM Outlines a Path to Align Health Financing Toward System-Wide Reform

The National Academy of Medicine (NAM) today released guidance on how to align the U.S. health system's financial incentives to achieve improved access, affordability, and better outcomes for every individual and community. The paper highlights the structural drivers of misaligned incentives and opportunities for discussion across the U.S. health care system.

According to the paper, prevailing payment structures, particularly fee-for-service, reward volume and intensity of services rather than prevention, coordination, or long-term outcomes. The result is systemic inefficiency, waste, persistent inequities, and gaps in care.

"Many innovative financing models have been tested over the past several decades, but most have remained limited to specific populations, care settings, or demonstration projects," said David Muhlestein, CEO of Simple Healthcare. "We have an opportunity now to move beyond isolated programs and pursue broader changes that align financial incentives across the health system around better health, better care, and better value."...

National Academies-Sciences-Engineering-Medicine [NASEM] - USA [to 01 Aug 2026]

<https://www.nationalacademies.org/newsroom>

News

Science for America's Next 250 Years — New Editorial

Announcement

In an editorial appearing in Proceedings of the National Academy of Sciences, former NAS president Marcia McNutt and Ellen Stofan, the Smithsonian Institution's undersecretary for science and research, share a vision for the future of science. McNutt and Stofan recently co-hosted a symposium that celebrated the past 250 years of American science and explored opportunities for continued innovation and discovery. "Anniversaries are not just moments to celebrate the past; they are calls to envision the future," they write.

Jul 28, 2026

PATH [01 Aug 2026]

<https://www.path.org/media-center/>

Newsroom [Selected]

PATH at AIDS 2026

Building resilient, integrated, people-centered systems to sustain HIV progress and advance Universal Health Coverage.

Rockefeller Foundation [to 01 Aug 2026]

<https://www.rockefellerfoundation.org/>

News and Announcements

No new digest content identified.

Sabin Vaccine Institute [01 Aug 2026]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified

UNAIDS [01 Aug 2026]

<http://www.unaids.org/en>

News, Stories, Updates

Press Release

Global HIV response falters as reemergence looms

In 2025, 1.2 million more people became infected with HIV and 570 000 more people died of AIDS-related illnesses as the world fell short of global targets. Without urgent action to meet the 2030 goals, more than 3 million could become infected with HIV by 2030.

RIO DE JANEIRO/GENEVA, 27 July 2026—A special report released by UNAIDS for the 26th International AIDS Conference taking place in Rio de Janeiro, Brazil from 27 to 31 July, shows that reductions to international funding and cuts to HIV prevention and community services are likely to lead to a resurgence of the epidemic...

UNICEF [to 01 Aug 2026]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements [Selected]

Statement 31 July 2026

Statement by UNICEF Acting Regional Director for the Middle East and North Africa, Abdul Fofana, as child casualties in Iran reportedly exceed 2,500 amid ongoing war

AMMAN, 31 July 2026 – , “As war reverberates in Iran and neighboring countries, children continue to be killed and maimed in the places where they should be safest – their homes, schools and communities. “Yesterday, in Qeshm Island, off the southern coast of Iran, a two-year-old child was reportedly killed alongside the child’s parents after a strike hit a residential...

Press release 28 July 2026

At least 23 children reportedly killed and 25 injured in Sudan’s conflict-afflicted North Kordofan in past two months

NEW YORK/NAIROBI/KHARTOUM, 28 July 2026 –, At least 23 children have reportedly been killed, with a further 25 reportedly injured in North Kordofan in the two months since the conflict intensified around Al Obeid in late May. The latest incident occurred on Friday 24 July in the Burbur area to the south of Al Obei...

Unitaid [01 Aug 2026]

<https://unitaid.org/>

News releases

Unitaid Board appoints Dr. Luis Pizarro as Unitaid’s next Executive Director

27 July 2026

The Unitaid Executive Board is delighted to announce the appointment of Dr. Luis Pizarro as the next Executive Director of Unitaid. Coming from DNDi, where he currently serves as Executive Director, he brings to Unitaid a unique combination of medical expertise, strategic leadership, and diplomatic acumen as well as a multicultural perspective shaped by professional experience across Africa, the Americas, Europe, and Asia...

Vaccine Equity Cooperative [nee Initiative] [01 Aug 2026]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified. [Last update Jun 30, 2023]

Vaccine Confidence Project [01 Aug 2026]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [01 Aug 2026]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

Vaccine Update Newsletter June/July 2026

Wellcome Trust [01 Aug 2026]

<https://wellcome.org/>

News. Opinion, Reports

No new digest announcements identified.

The Wistar Institute [to 01 Aug 2026]
<https://www.wistar.org/news/press-releases>

Press Releases

July 30, 2026

The Wistar Institute Recruits Christopher McGinnis

McGinnis studies cancer microenvironment complexity to create metastasis-targeted cancer therapeutics

July 30, 2026

Wistar Scientists Identify Fructose as a Surprise Driver of Cancer Spread

Researchers from Dr. Katherine Aird's lab found that ovarian cancer cells that survive chemotherapy release fructose as a cellular signaling molecule.

July 29, 2026

The Wistar Institute Receives Grant from the V Foundation for Cancer Research to Advance Melanoma Studies

Dr. Jessive Villanueva's lab has received a Breaking Barriers in Cancer Research Award from the V Foundation for Cancer Research. The \$800,000 grant, enables her lab to pursue research into new poten...

World Bank [to 01 Aug 2026]

<http://www.worldbank.org/en/news/all>

News [Selected]

No new digest announcements identified.

WFPHA: World Federation of Public Health Associations [01 Aug 2026]

<https://www.wfpha.org/>

Blog, Events

No new digest announcements identified.

World Medical Association [WMA] [to 06 Sep 025]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest announcements identified.

World Organisation for Animal Health [WOAH/OIE] [01 Aug 2026]

<https://www.oie.int/>

Latest News

No new digest announcements identified.

.....

.....

ARM [Alliance for Regenerative Medicine] [01 Aug 2026]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest announcements identified.

BIO [01 Aug 2026]

<https://www.bio.org/press-releases>

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [01 Aug 2026]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest announcements identified.

EFPIA – European Federation of Pharmaceutical Industries and Associations

<https://www.efpia.eu/news-events/>

News & Events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [01 Aug 2026]

<https://internationalbiotech.org/>

News

No new digest announcements identified.

IFPMA [01 Aug 2026]

<https://ifpma.org/>

News & Resources

Report 29 Jul 2026

[Healthy planet, healthy people: The innovative pharmaceutical industry's contribution to the Kunming-Montreal Global Biodiversity Framework](#)

Human health and nature are deeply interconnected. Land-use change, climate change, and pollution drive biodiversity loss and reshape the environmental conditions on which human well-being depends. Land-use change increases the risk of zoonotic spillover and emerging infectious diseases; climate change alters the distribution of vector- and waterborne diseases and stresses threatened species; and pollution adds...

International Alliance of Patients' Organizations – IAPO [01 Aug 2026]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [01 Aug 2026]

<http://www.phrma.org/>

Press Releases

No new digest announcements identified.

.....
.....

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

We recognize that this listing is indicative but certainly not exhaustive. We invite nomination of other vaccine developers for potential addition to those monitored below.

AstraZeneca

Press Releases - *No new digest announcements identified.*

Bavarian Nordic

Latest News - *No new digest announcements identified....*

BioCubaFarma – Cuba

Últimas Noticias - *No new digest announcements identified.*

Biological E

News - *No new digest announcements identified.*

BioNTech

Press Releases

07.29.2026

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

- Data indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages
- More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globally
- Vaccine demonstrates a favorable safety and efficacy profile
- Shipping will begin soon to ensure rapid access of this season's vaccine

Boehringer

Press Releases - *No new digest announcements identified.*

CanSinoBIO

News - *Website not responding at inquiry.*

CIGB

Latest News - *No new digest announcements identified.*

CinnaGen – Iran

CinnaGen News - *Website not responding at inquiry.*

Clover Biopharmaceuticals – China

News - *No new digest announcements identified.*

CSL Seqirus

News Releases - *No new digest announcements identified.*

Curevac

News - *Website now directs to BioNTech site*

Dailchi Sankyo

Press Releases - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

29 July 2026

[Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026](#)

28 July 2026

[GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK](#)

EuBiologics, S Korea

News - No new digest announcements identified.

HIPRA

Press releases

[HIPRA receives European Commission marketing authorisation for its COVID-19 vaccine adapted to the XFG.1.1 variant](#)

31-07-2026

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified.

Merck

News releases - No new digest announcements identified.

Moderna

News and Blog Posts - No new digest announcements identified.

Nanogen

News - No new digest announcements identified.

Novartis

News - No new digest announcements identified.

Novavax

Press Releases - No new digest announcements identified.

Pfizer

Recent Press Releases

07.29.2026

[European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union](#)

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Samsung Biologics

[Latest News](#) - No new digest announcements identified

Sanofi Pasteur

[Press Releases](#) - No new digest announcements identified

Serum Institute

[News & Announcements](#) - No new digest announcements identified.

Sinopharm/WIBPBIBP

[News](#) - No new digest announcements identified.

Sinovac

[Press Releases](#) - No new digest announcements identified.

SK Biosciences

[Press Releases](#) - No new digest announcements identified.

Takeda

[Newsroom](#) - No new digest announcements identified.

Valneva

[Press Releases](#) - No new digest announcements identified.

WestVac Biopharma

[Media](#) - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[Website](#) *[No News/Announcements page identified]*

.....
.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....
.....

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 17 2026 Issue 2

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 12: E823-875 December 2025

<https://journalofethics.ama-assn.org/issue/aging-bad-you>

Aging Is Bad for You?

At some point along life's trajectory, growing becomes aging. Gerotherapeutics—biologically-based approaches to health that target processes of aging—seem poised to respond. This theme issue investigates ethical valences of what gerotherapeutics suggest about our socially, culturally, and historically entrenched patterns of pathologizing and medicalizing aging. Advancement in our understanding of physiological mechanisms of aging has prompted some to reconceive lifespans as health spans. Geroscience also suggests the need to critically evaluate whether and to what extent we should think of anti-aging ventures as legitimate enterprises of health care. Normative roles played by aging in our personal and relational narratives, in our expectations about how duration and quality of life confer value to life, and in how life extension promotes or undermines our notions of wisdom and a good life are all at stake.

American Journal of Human Genetics

Jul 02, 2026 Volume 113 Issue 7 p1365-1582

<https://www.cell.com/ajhg/current>

This month in The Journal

Paul W. Hook, Alyson B. Barnes

Nondisjunction, the failure of chromosomes to separate, results in aneuploidies, in which cells have an abnormal number of chromosomes. Centromeres play an essential role in segregation of homologous chromosomes and sister chromatids. It has been hypothesized that centromere size, sequence, allelic difference, and epigenetic features might influence nondisjunction and, therefore, aneuploidy risk. Until recently, however, it has been difficult to study the sequence of human centromeres due to limitations of short-read sequencing.

[Reviewed earlier]

American Journal of Infection Control

August 2026 Volume 54 Issue 8 p829-930

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

August 2026 Volume 71 Issue 2

<https://www.ajpmonline.org/current>

[New issue; No digest content identified]

American Journal of Public Health

August 2026 116(8)

<http://ajph.aphapublications.org/toc/ajph/current>

OPEN-THEMED RESEARCH

The One Health Blind Spot at the Human–Animal Interface in US Influenza Surveillance

Cole King MPH and A. Paige Adams DVM, PhD

American Journal of Tropical Medicine and Hygiene

Volume 115 (2026): Issue 1 (Jul 2026)

<https://www.ajtmh.org/view/journals/tpmd/115/1/tpmd.115.issue-1.xml>

[Reviewed earlier]

Annals of Internal Medicine

July 2026 Volume 179, Issue 7

<https://www.acpjournals.org/toc/aim/current>

Editorials

Pragmatic Trials: The Importance of Foundational Research, Fidelity, Implementation, and Context

Mary D. Naylor, PhD, RN and Karen B. Hirschman, PhD, MSW

Pages:1051–1052

Artificial Intelligence – An International Journal

Volume 358 September 2026

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/358/suppl/C>

[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 01 Aug 2026)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 01 Aug 2026)

Equity in healthcare financing and access to care among vulnerable populations in Africa: a systematic review

Glory Olalekan Adebajo, Gbenga Joseph Alabi, Damilola Jeremiah Ayowole

Systematic Review Open access 29 July 2026

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 01 Aug 2026)

Marburg Virus Disease (MVD): a rapid systematic review with narrative synthesis of epidemiology, clinical presentation, diagnostics, management, and public-health response

Deresse Sinamaw Asmare

Systematic Review Open access 31 July 2026

Epidemiology, vaccine effectiveness, and risk factors of pertussis in Xinjiang children: a retrospective study

Liang Ru, Hongtao Zhu, Mei Yan
Research Open access 30 July 2026

BCG vaccination and household TB exposure in childhood tuberculosis: a community-based case-control study in rural Bangladesh

Taifur Rahman, Satyajit Kundu, Ahmed Hossain
Research Open access 27 July 2026

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>
(Accessed 01 Aug 2026)
[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>
(Accessed 01 Aug 2026)

Impact of COVID-19 pandemic on childhood immunization coverage in Indonesia: lesson learned from a nationwide analysis of the Expanded Programme on Immunization

Amalia Nurina, Evelyn Puspaningrum, Henry Surendra
Research Open access 21 July 2026

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>
(Accessed 01 Aug 2026)

Acceptability and uptake of COVID-19 vaccines among pregnant and lactating women seeking services at a tertiary public hospital in Kampala, Uganda

Elizabeth B. Katana, Eva Agnes Laker Odongpiny, Catriona Waitt
Research Open access 01 Aug 2026

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>
(Accessed 01 Aug 2026)

Determinants of delayed detection and reporting of epidemic-prone diseases in Sub-Saharan Africa: a systematic review and CFIR-guided synthesis

Vivian Nwechi, Augustine Usman Adaka, Polycarp Dauda Madaki
Systematic Review Open access 01 August 2026

Factors influencing HPV vaccination behavior among Chinese women aged 18–45 years based on the information-motivation-behavioral skills model: a cross-sectional study

Jingyi Chen, Jing Tan, Xiao Peng
Research Open access 25 July 2026

High intention, low uptake: HPV vaccination knowledge, attitudes, and behavior among women attending a tertiary gynecology clinic in Turkey

Esra Öncü, Zeynep Ece Utkan Korun, Necip Erkut Attar

Research Open access 24 July 2026

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 01 Aug 2026)

[No new digest content identified]

BMJ Evidence-Based Medicine

August 2026 - Volume 31 - 4

<https://ebm.bmj.com/content/31/4>

[Reviewed earlier]

BMJ Global Health

July 2026 - Volume 11 - 7

<https://gh.bmj.com/content/11/7>

Commentary

[Beyond elimination: reframing measles vaccination strategies](#) (21 July, 2026)

Laurence Monnais, Ludovico Gennaro Cobuccio, Pierre-Alex Crisinel, Amel Filali, Pascale Hancart Petitet, Heather MacDougall, Raul Antonio Necochea, Noémi Tousignan

Essay

[Mpox in Sierra Leone and the Mano River Union: an epidemic unfolding in real time](#) (31 July, 2026)

Nelson Aghogho Evaborhene, Sulaiman Lakoh, Darlinda Jiba, Chizaram Onyeaghala

Bulletin of the Atomic Scientists

DIGITAL MAGAZINE - May 2026

<https://thebulletin.org/magazine/2026-05/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 104, Number 7, July 2026, 441-524

<https://www.who.int/publications/journals/bulletin>

[Reviewed earlier]

Cell

Jul 09, 2026 Volume 189 Issue 14 p4185-4518

<https://www.cell.com/cell/current>

Articles

[Reviewed earlier]

Cell and Gene Therapy Insights

February 2026 Issue, Volume 12 Issue 1

<https://www.insights.bio/cell-and-gene-therapy-insights/journal/283/volume-12-issue-1>

[Reviewed earlier]

Child Care, Health and Development

Volume 52, Issue 4 July 2026

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 120, Issue 2 Pages: 289-562 August 2026

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

August 2026 Volume 48 Issue 8 p677-808

<http://www.clinicaltherapeutics.com/current>

Special Issue on "Advancing Diversity, Racial Equity & Inclusion in Clinical Research - Part II"

[Reviewed earlier]

Clinical Trials

Volume 23 Issue 3, June 2026

<https://journals.sagepub.com/toc/CTJ/current>

Articles

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 01 Aug 2026]

[Essential medicines in conflict-affected settings: a systematic review of accessibility and affordability across fragile health systems](#)

Tracy Kuo Lin, Atousa Bonyani

Review Open access 30 July 2026

Contemporary Clinical Trials

Volume 166 July 2026

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/166/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 9 Issue 3, June 2026

<https://journals.sagepub.com/toc/tcja/9/3>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025

<https://link.springer.com/journal/40142/volumes-and-issues/13-1>
[Reviewed earlier]

Current Medical Research and Opinion

Volume 42, Issue 1, 2026

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

August 2026 - Volume 39 - Issue 4

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 01 Aug 2026]

[No new digest content identified]

Cytotherapy

September 2026 Volume 28 Issue 9

<https://www.isct-cytotherapy.org/current>

[Reviewed earlier]

Developing World Bioethics

Volume 26, Issue 2 Pages: 81-130 June 2026

<https://onlinelibrary.wiley.com/toc/14718847/current>

Special Issue: Military Global Health Engagements

[Reviewed earlier]

Development in Practice

Volume 36, 2026 Issue 4

<https://www.tandfonline.com/toc/cdip20/36/4?nav=tocList>

[Reviewed earlier]

Development Policy Review

Volume 44, Issue 4 July 2026

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 20 - 2026

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 50, Issue 3 July 2026

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

eBioMedicine

Volume 128 June 2026

<https://www.sciencedirect.com/journal/ebiomedicine/vol/128/suppl/C>

[Reviewed earlier]

EMBO Reports

Volume 27, Issue 13 July 2026

<https://link.springer.com/journal/44319/volumes-and-issues/27-13>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 32, Number 6—June 2026

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 55 June 2026

<https://www.sciencedirect.com/journal/epidemics/vol/55/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 154 - 2026

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 48, Issue 3 Pages: 1-46 May–June 2026

<https://onlinelibrary.wiley.com/toc/25782363/current>

[Reviewed earlier]

Ethics & International Affairs

Volume 40 - Issue 1 - Spring 2026

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 33 2025

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/33/suppl/Cc>
[Reviewed earlier]

The European Journal of Public Health

Volume 36, Issue 3, June 2026

<https://academic.oup.com/eurpub/issue/36/3>

[Reviewed earlier]

Expert Review of Vaccines

Volume 25, 2026 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

May/June 2026 Volume 105, Number 3

<https://www.foreignaffairs.com/issues/2026/105/3>

[Reviewed earlier]

Forum for Development Studies

Volume 53, 2026 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

The Rebirth of the Global South: Geopolitics, Imageries, and Developmental Realities

[New issue: No digest content identified]

Frontiers in Genetics

<https://www.frontiersin.org/journals/genetics>

[Accessed 01 Aug 2026]

Mini Review

Published on 29 Jul 2026

[Artificial intelligence in peptide cancer vaccine design: from neoantigen discovery to immunogenicity prediction](#)

Petar Brlek, et al.

Original Research

Published on 29 Jul 2026

[Five-year outcomes of next-generation sequencing implementation at a Brazilian public health system reference centre for rare diseases](#)

Natana Chaves Rabelo, et al.

Frontiers in Genome Editing

<https://www.frontiersin.org/journals/genome-editing>

[Accessed 01 Aug 2026]

Policy and Practice Reviews

Published on 29 Jul 2026

[Navigating the human gene editing scene and proposing a new governance framework in Africa: from knowledge to policy to action](#)

Abdallah Borham. Et al.

Frontiers in Medicine

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 01 Aug 2026]

[No new digest content identified]

Gene Therapy – Nature

Volume 33 Issue 3, May 2026

<https://www.nature.com/gt/volumes/33/issues/3>

[Reviewed earlier]

Genetics in Medicines

Volume 28, Issue 7 July 2026

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/28/issue/7>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 01 Aug 2026]

[No new digest content identified]

Global Health Action

Volume 19, Issue 1 (2026)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

December 2025 | Volume 13 | Number 2

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 01 Aug 2026]

[No new digest content identified]

Global Public Health

Volume 21, Issue 1 (2026)

<http://www.tandfonline.com/toc/rqph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 01 Aug 2026]

[**From rupture to recourse: building a new economic order for health**](#)

Ronald Labonté

Editorial Open access 20 July 2026 Article: 59

Health and Human Rights

Volume 28, Issue 2, June 2026

<https://www.hhrjournal.org/volume-28-issue-1-june-2026/>

Special Section: Children's Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 21 - Issue 3 - July 2026

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 41, Issue 6, June 2026

<https://academic.oup.com/heapol/issue/41/6>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 01 Aug 2026]

[Reviewed earlier]

Human Gene Therapy

Volume 37 Issue 13-14, July 2026

<https://journals.sagepub.com/toc/hgta/37/13-14>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

[Accessed 01 Aug 2026]

[No new digest content identified]

Immunity

Jul 14, 2026 Volume 59 Issue 7 p1777-2054

<https://www.cell.com/immunity/current>

[New issue; No digest content identified]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 01 Aug 2026]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

Latest articles

[No new digest content identified]

International Health

Volume 18, Issue 4, July 2026

<https://academic.oup.com/inthealth/issue/18/4>

[Reviewed earlier]

International Human Rights Law Review

Volume 15 (2026): Issue 1 (Jun 2026)

<https://brill.com/view/journals/hrlr/hrlr-overview.xml>

[Reviewed earlier]

The International Journal of Children's Rights

Volume 34 (2026): Issue 2 (Jun 2026)

<https://brill.com/view/journals/chil/34/1/chil.34.issue-2.xml>

Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 13 No. 6 (2026): June 2026

<https://www.ijcmph.com/index.php/ijcmph/issue/view/137>

Articles

[Reviewed earlier]

International Journal of Epidemiology

Volume 55, Issue 3, June 2026

<https://academic.oup.com/ije/issue/55/3>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 19, Issue 2 22 April 2026

<https://www.emerald.com/ijhrh/issue/19/2>

[Reviewed earlier]

JAMA

July 28, 2026, Vol 336, No. 4, Pages 271-352

<https://jamanetwork.com/journals/jama/currentissue>

AI in Medicine

[From Silicon Valley to the Vatican—The Expanding Debate on AI Ethics](#)

Roy Perlis, MD, MSc; Yulin Hswen, ScD, MPH

JAMA Health Forum

June 2026, Vol 7, No. 6

<https://jamanetwork.com/journals/jama-health-forum/issue>

[Reviewed earlier]

JAMA Pediatrics

June 2026, Vol 180, No. 6, Pages 593-706

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBIR Evidence Synthesis

June 2026 - Volume 24 - Issue 6

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

June 2026 Volume 78 Issue 6 p835-956

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 85 (2026)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 51, Issue 3 June 2026

<https://link.springer.com/journal/10900/volumes-and-issues/51-3>

[Reviewed earlier]

Journal of Development Economics

Volume 183 September 2026

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/183/suppl/C>

Research article Abstract only

[The lasting effects of early childhood interventions: The National Vaccination Commando Program in Burkina Faso](#)

Richard Daramola, Md Shahadath Hossain, Harounan Kazianga, Karim Nchare

Article 103851

Journal of Empirical Research on Human Research Ethics

Volume 21 Issue 3, July 2026

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

June 2026 - Volume 80 - 6

<https://jech.bmj.com/content/80/3>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 19, Issue 2 June 2026

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 22, Issue 1 (2026)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 37, Number 2, May 2026

<https://muse.jhu.edu/issue/56930>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 28, Issue 3 June 2026

<https://link.springer.com/journal/10903/volumes-and-issues/28-3>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 24, Issue 2 (2026)

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of International Development

Volume 38, Issue 5 Pages: 773-931 July 2026

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Law, Medicine & Ethics

Volume 54 - Issue 1 - Spring 2026

<https://www.cambridge.org/core/journals/journal-of-law-medicine-and-ethics/latest-issue>

[Reviewed earlier]

Journal of Medical Ethics

August 2026 - Volume 52 - 8

<http://jme.bmj.com/content/current>

Original research

[Balancing public health and individual autonomy: a study of China's vaccination policy](#) (11

August, 2025)

Jichao Wang, Xiaomei Zhai

Abstract

The article examines China's vaccination policy, focusing particularly on childhood immunisation and pandemic vaccines. Although China's laws require individuals to engage in the vaccination decision-making process, the policy does not enforce mandatory vaccination through penalties. Instead, it emphasises informed decision-making, allowing and supporting individuals to choose whether to vaccinate or adopt other preventive measures based on their best health interests. The legal framework includes obligations for guardians to make vaccination decisions for their children, with mechanisms to encourage compliance through checking vaccination status and guiding guardians to vaccination services, rather than punishing vaccine refusal. This approach aligns with the Siracusa Principles, advocating the least restrictive measures necessary to protect public health. The article concludes that China's vaccination policy is best understood as 'mandatory decision-making', a system that balances public health objectives with individual autonomy by making the decision-making process mandatory while keeping the actual vaccination decision voluntary.

Journal of Patient-Centered Research and Reviews

Volume 13, Issue 2 (2026)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 294 July 2026

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/294/suppl/C>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 19, 2026 Issue 1

<https://www.tandfonline.com/toc/jppp20/19/1?nav=tocList>

[Reviewed earlier]

Journal of Public Health Management & Practice

September/October 2026 - Volume 32 - Issue 5

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[New issue; No digest content identified]

Journal of Public Health Policy

Volume 47, Issue 2 June 2026

<https://link.springer.com/journal/41271/volumes-and-issues/47-2>

[Reviewed earlier]

Journal of the Royal Society – Interface

Volume 23, Issue 240 1 July 2026

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 33, Issue 5, July 2026

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

The Lancet

Aug 01, 2026 Volume 408 Number 10553 p381-490

<https://www.thelancet.com/journals/lancet/issue/current>

Comment

Hantavirus: the need for a rapid regional response platform in Latin America

Patricia J Garcia, et al.

Viewpoint

Hepatitis A prevention in the USA depends on routine universal childhood vaccination

Noele P Nelson, John W Ward

On Jan 5, 2026, the Acting Director of the US Centers for Disease Control and Prevention (CDC) signed a decision memorandum from the heads of the National Institutes of Health, the Centers for Medicare & Medicaid Services, and the US Food and Drug Administration, which removed vaccines against meningococcal disease, influenza, COVID-19, hepatitis A, and hepatitis B, including the birth dose, as routinely recommended vaccines for all children.¹ Instead, except for certain groups at high risk, these vaccines were recommended for children based on shared clinical decision making.² The rationale for this decision was driven by an assessment comparing the US immunisation schedule to other countries, published a few days earlier by the US Department of Health and Human Services.³ These changes to the hepatitis A vaccine schedule and other changes to vaccine policy have been challenged and temporarily blocked by a preliminary court decision.⁴ As authors of previous CDC recommendations for hepatitis A vaccination,^{5,6} in this Viewpoint, we provide additional information to refute the US Department of Health and Human Services' claims against universal hepatitis A vaccination, and to support continued vaccination of all children to prevent hepatitis A among children and adults.

The Lancet Child & Adolescent Health

Aug 2026 Volume 10 Number 8 p541-612, e23

<https://www.thelancet.com/journals/lanchi/issue/current>

Editorial

Children and adolescents in the humanitarian response

The Lancet Child & Adolescent Health

World Refugee Day on June 20 is a sobering reminder that 1·4% of the world's population is forcibly displaced today. According to the UNHCR's latest Global Trends report, at the end of 2025, there were an estimated 41·6 million refugees worldwide and 68·7 million people displaced within their own country because of conflict or violence. Children (<18 years) are disproportionately affected, accounting for 29% of the world's population but 39% of forcibly displaced people. The current

situation is grave. Modern conflicts are increasingly violent, with explosive weapons being used in densely populated urban areas. Health-care workers, hospitals, and schools are deliberately targeted with impunity. Aid is weaponised and transactional. Civilians—many of them children and adolescents—account for the majority of warfare fatalities. In addition to conflict and political instability, climate-related crises, public health emergencies, and other drivers mean that the present humanitarian need is unprecedented, at a time of geopolitical fragmentation and major funding cuts from the USA and European donors. As the [Johns Hopkins Center for Humanitarian Health–*Lancet* Commission on health, conflict, and forced displacement](#) argues, the humanitarian system is failing to protect health and no longer fit for purpose—a bold transformation is urgently needed.

Children bear the brunt of war and conflict. In 2024, the UN verified 41 370 [grave violations](#) (eg, killing, maiming, denial of humanitarian access, recruitment of child soldiers) against 22 495 children, with the highest numbers recorded in Israel, Palestine, the Democratic Republic of the Congo, Somalia, Nigeria, and Haiti. The [Global Coalition to Protect Education from Attack](#) recorded at least 8566 attacks on education in 2024–25, a more than 40% increase compared to 2022–23, with over 10 600 students and staff killed, injured, abducted, or otherwise harmed. [Blast and crush injuries](#) are particularly deadly for children and can cause serious long-term disability and psychological trauma in survivors; Gaza now has the largest cohort of child amputees in modern history.

Conflict and displacement also have much wider indirect effects on child health and wellbeing, particularly for the youngest. The Commission notes that the severe disruption to maternal, neonatal, and child health services has increased obstetric and neonatal complications and mortality (eg, from prematurity, perinatal asphyxia, and neonatal sepsis), while childhood immunisation services are often the first to collapse when conflict escalates. Other major causes of child death include diarrhoeal diseases (where 80% of mortality occur in children aged <2 years), malaria, and malnutrition. These health risks are compounded by degraded shelter conditions, food insecurity, and limited access to safe water and sanitation. Forced displacement also creates barriers to health care and education, especially for internally displaced children.

Echoing the Commission's four recommendations—invert the power, end impunity, fix the money, and uphold health for all—the needs and voices of children and young people must be centred in the humanitarian response. Children, as well as their homes, schools and communities, must never be targeted in warfare; accountability must be enforced through law, ethics, humanitarian principles, and action. Health response must be contextually adapted and locally anchored. Shifting power to affected communities and locally legitimate actors—including child health professionals—is therefore key to ensure that services can meet the unique needs of children, including essential newborn care, availability of child-friendly formulations and medical devices, pain management, rehabilitation, and mental health support. Equity and continuity of care must be priorities, especially for groups at heightened risks, such as those who are malnourished, pregnant, and living with disabilities and chronic health conditions.

We applaud child health professionals who are already working tirelessly to advocate for children, and urge decision makers to share power with young people and see them as agents for change rather than just beneficiaries. There are ample examples of young people in conflict zones creating positive change. From [youth-led initiatives](#) that facilitate dialogues before tensions escalate in Nigeria and creation of online tools to flag signs of trouble in the Sahel, to rebuilding cities and towns in [Ukraine](#) and fighting misinformation in [Cox's Bazar](#), young people are actively shaping their present and future. The humanitarian system needs a radical transformation, and this includes a radical sharing of power with children, young people, and the child health community.

Articles

[**Immunogenicity and safety of a pentavalent meningococcal MenABCWY vaccine in healthy adolescents and young adults: a phase 3, multicountry, randomised, observer-blinded, active-controlled non-inferiority trial**](#)

Lars Ostergaard, et al.

Health Policy

Tuberculosis research principles and priorities in children and adolescents: an international consensus statement

Morine P Sekadde, et al. on behalf of the Child and Adolescent TB Working Group

Summary

Each year, an estimated 1·9 million children (aged 0–9 years) and adolescents (aged 10–19 years) develop tuberculosis disease. Tuberculosis ranks among the top ten causes of death in children younger than 5 years. The primary driver of tuberculosis-related mortality in children and young adolescents is the failure to detect and treat the disease; more than 95% of tuberculosis deaths occur in children who were never initiated on tuberculosis treatment. To increase the quantity and quality of tuberculosis research required to strengthen clinical care and public health practice, the Child and Adolescent TB Working Group and its Secretariat at the WHO led a modified Delphi consensus process to generate core research principles and priorities along each step of the tuberculosis care cascade. An 11-member writing group drafted an initial list of principles and priorities, which were ranked by members of the consensus panel in each Delphi round. Principles and priorities that did not meet the consensus threshold were modified based on written qualitative feedback from the consensus panel and one-time input from other members of the Child and Adolescent TB Working Group at the group's 2024 annual meeting. Eight research principles and 21 research priorities emerged from two Delphi rounds. The research priorities have strong potential for translation into interventions, particularly in relation to diagnostics, shorter regimens, and tuberculous meningitis. With recently reduced tuberculosis research funding, these principles and priorities will focus research efforts to maximise clinical and public health impact.

Lancet Digital Health

Jul 2026 Volume 8 Number 7

<https://www.thelancet.com/journals/landig/issue/current>

Viewpoint

Navigating the promise and pitfalls of dashboards in health policy decision making: experiences from Ghana, India, and South Africa

Luxsena Sukumaran, et al.

Precision medicine's inevitable trajectory toward rare-disease-sized cohorts: implications for machine learning and deep learning

Andrew Janowczyk, et al.

Lancet Global Health

Jul 2026 Volume 14 Number 7

<https://www.thelancet.com/journals/langlo/issue/current>

Articles

Global, regional, and national impact of the Expanded Programme on Immunization against 14 pathogens from 1974 to 2024: an economic evaluation

Xiaozhen Lai, et al.

... The 50-year EPI has proven highly cost-effective at global, regional, and national levels, and remains a worthwhile investment. The EPI delivered impactful life-saving benefits and favourable economic returns, especially in high-burden and low-income settings.

Health Policy

Rwanda's lessons for strengthening Africa's response to current Marburg virus disease outbreaks

Claude Mambo Muvunyi, et al.

Lancet Infectious Diseases

Aug 2026 Volume 26 Number 8 p751-870, e268-e320

<https://www.thelancet.com/journals/laninf/issue/current>

Articles

[Measuring population immunity against influenza using individual antibody titres: a multicountry, retrospective observational study](#)

WeiJia Xiong, et al.

[Immunogenicity of high-dose recombinant influenza vaccine versus standard-dose egg-grown and cell-grown vaccines among frequently and infrequently vaccinated young adults in Singapore: a randomised, controlled, double-blind, single-centre, phase 4 clinical trial](#)

Sheena G Sullivan, et al.

[Immunogenicity, reactogenicity, and safety of a reduced-interval 4CMenB primary immunisation schedule in UK infants: a multicentre, open-label, assessor-blinded, phase 4 randomised controlled trial](#)

Natasha Thorn, et al.

[Real-world effectiveness of 20-valent pneumococcal conjugate vaccine against all-cause outcomes among Medicare beneficiaries aged 65 years and older in the USA: a retrospective cohort study](#)

Amanda C Miles, et al.

[Safety and immunogenicity of a single-dose adenovirus-vectored rabies vaccine over 1 year in adults and children in Tanzania: interim data from an ongoing, partly randomised, controlled, phase 1b/2 trial](#)

Adam J Ritchie, et al. on behalf of the RAB002 study team

Lancet Public Health

Aug 2026 Volume 11 Number 8 e472-e582

<https://www.thelancet.com/journals/lanpub/issue/current>

Editorial

[Ebola: lessons from the past](#)

The Lancet Public Health

... Community engagement is central because Ebola is a social challenge as well as a virological one. Trust is a defining theme of every major Ebola outbreak. Successful outbreak control depends on communities trusting health authorities, clinicians, and responders enough to report symptoms, accept isolation, cooperate with contact tracing, and modify burial practices. However, establishing this trust is particularly challenging in DR Congo because of insecurity and conflict. African and local leadership is essential to gain trust. Community-led information initiatives involving village leaders, trusted faith-based organisations, local non-governmental organisations, and other respected partners are crucial. Testimonials from Ebola survivors are also important for dispelling false rumours and championing public health measures; they were key in gaining local trust during the west African outbreak.

Declaring the PHEIC is only the beginning. Containing the outbreak will depend on adequate and accessible financing, African and local leadership, establishing trust in communities, rapid implementation of the WHO–Africa CDC plan, and sustained international support. Thousands of lives depend on it.

Articles

Estimating optimal levels of WHO Access, Watch, Reserve (AWaRe) antibiotic use in 186 countries, territories, and areas on the basis of clinical infection and resistance burden

Aislinn Cook, et al.

Global, regional, and national trends in the morbidity gap and contributing diseases, injuries, and risk factors, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Simon I Hay, et al.

Lancet Respiratory Medicine

Aug 2026 Volume 14 Number 8 p647-746, e51-e56

<https://www.thelancet.com/journals/lanres/issue/current>

[New issue; No digest content identified]

Maternal and Child Health Journal

Volume 30, Issue 6 June 2026

<https://link.springer.com/journal/10995/volumes-and-issues/30-6>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 46 Issue 6, August 2026

<https://journals.sagepub.com/toc/MDM/current>

[Reviewed earlier]

Medical Law International

Volume 26 Issue 2, June 2026

<https://journals.sagepub.com/toc/MLI/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 104, Issue 2 Pages: 293-580 June 2026

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Molecular Therapy

Jul 01, 2026 Volume 34 Issue 7 p3709-4338

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

Nature

Volume 655 Issue 8125, 30 July 2026

<https://www.nature.com/nature/volumes/655/issues/8125>

Editorial 29 Jul 2026

Polio will come roaring back if the task of eradicating it isn't finished soon

Eliminating polio is within reach — if countries see it as an essential public-health priority.

Comment 27 Jul 2026

Researchers are building computers that run on brain organoids — but have neglected a major ethical issue

People who give tissue samples for biomedical research might have no idea that their cells are being used for biocomputers.

Nada S. Salem, Jianping Fu, Insoo Hyun

Article Open Access 17 Jun 2026

Towards autonomous medical artificial intelligence agents

A large language model artificial intelligence agent operating in a sandboxed electronic health record system can autonomously take patient histories, order tests, interpret findings, diagnose conditions and propose treatments, outperforming experienced clinicians while adhering to safety standards and clinical guidelines.

Dyke Ferber, Lars Hilgers, Jakob Nikolas Kather

Article Open Access 17 Jun 2026

Towards conversational artificial intelligence for disease management

Advances to the artificial intelligence system AMIE enable it to manage disease across multiple visits while reasoning over a corpus of clinical guidelines and patient history, outperforming primary care physicians on management reasoning tasks.

Valentin Liévin, Anil Palepu, Mike Schaekermann

Nature Biotechnology

Volume 44 Issue 7, July 2026

<https://www.nature.com/nbt/volumes/44/issues/7>

Editorial 06 Jul 2026

Quantum computing in transition

Hybrid quantum–classical computers will achieve quantum advantage in biotechnology, bridging the time until a full quantum computer becomes available.

Comment 26 May 2026

A framework for building a synthetic cell from the SynCell Asia Initiative

Building a living cell from scratch requires overcoming a bottleneck that has remained unresolved despite decades of progress: orchestrating the spatiotemporal integration of core functional modules. To tackle this barrier, the SynCell Asia Initiative outlines a strategy for developing core functional modules followed by their systems-level integration through the establishment of a centralized, artificial intelligence (AI)-driven biofoundry.

Zhuojun Dai, Wataru Aoki, Chenli Li

Perspective 01 Jun 2026

Decoding the origins of cellular self-organization for engineered biology

This Perspective positions cellular self-organization as a foundational principle for the origin of multicellular life and discusses how decoding this concept with stem cell-based models will advance biological engineering.

Qi Chen, Magdalena Zernicka-Goetz

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>
(Accessed 01 Aug 2026)
[Reviewed earlier]

Nature Genetics

Volume 58 Issue 7, July 2026

<https://www.nature.com/ng/volumes/58/issues/7>

Comment 19 May 2026

[Towards a decentralized future for open-science databases](#)

Large-scale biological data repositories, particularly when deployed as single, non-mirrored instances or governed within narrow contexts, face structural vulnerabilities, from cyberattacks to funding disruptions. We propose a hybrid framework that integrates federated and decentralized models to ensure the resilience, sustainability and FAIR/CARE stewardship of scientific data as a global public good.

Gaurav Sharma, Viorel Munteanu, Serghei Mangul

Nature Human Behaviour

Volume 10 Issue 7, July 2026

<https://www.nature.com/nathumbehav/volumes/10/issues/7>

Correspondence 15 Jun 2026

[US funding cuts offer a rare chance to remodel Global North–Global South research collaboration](#)

Andrew Reid Bell, Sarobidy Rakotonarivo, Wei Zhang

Nature Medicine

Volume 32 Issue 7, July 2026

<https://www.nature.com/nm/volumes/32/issues/7>

[New issue; No digest content identified]

Nature Reviews Drug Discovery

Volume 25 Issue 8, August 2026

<https://www.nature.com/nrd/volumes/25/issues/8>

[New issue; No digest content identified]

Nature Reviews Genetics

Volume 27 Issue 8, August 2026

<https://www.nature.com/nrg/volumes/27/issues/8>

[New issue; No digest content identified]

Nature Reviews Immunology

Volume 26 Issue 8, August 2026

<https://www.nature.com/nri/volumes/26/issues/8>

[New issue; No digest content identified]

New England Journal of Medicine

Volume 395 No. 5 July 30, 2026
<https://www.nejm.org/toc/nejm/medical-journal>
[New issue; No digest content identified]

NEJM Evidence

Volume 5 No. 6 June 2026
<https://evidence.nejm.org/toc/evid/current>
NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
[Reviewed earlier]

njp Vaccines

<https://www.nature.com/npjvaccines/>
[Accessed 01 Aug 2026]
[Reviewed earlier]

Pediatrics

Volume 158, Issue 1 July 2026
<https://publications.aap.org/pediatrics/issue/158/1>
[Reviewed earlier]

PharmacoEconomics

Volume 44, Issue 8 August 2026
<https://link.springer.com/journal/40273/volumes-and-issues/44-8>
[New issue; No digest content identified]

PLoS Biology

<https://journals.plos.org/plosbiology/>
(Accessed 01 Aug 2026)
[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>
(Accessed 01 Aug 2026)
[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60
(Accessed 01 Aug 2026)
[No new digest content identified]

PLoS Medicine

<https://journals.plos.org/plosmedicine/>

(Accessed 01 Aug 2026)
[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 01 Aug 2026)
[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 01 Aug 2026]

"... Infections are not confined in labs...": Community engagement for Controlled Human Infection Studies: Opinions of researchers, bioethicists and research regulators in Uganda

Winfred Nazziwa, Stella Neema, Alison M. Elliott, Samson B. Kaboko, Erisa Mwaka

Research Article | published 28 Jul 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0353964>

Parents' role as advocates for and against childhood vaccination: Findings from a nationally representative survey

Kathryn L. Kennedy, Tara L. Queen, Mallory K. Ellingson, Emma H. Elias, William A. Calo, Nora E.

Rosenberg, Noel T. Brewer, Melissa B. Gilkey

Research Article | published 23 Jul 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0354147>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 01 Aug 2026]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

July 28, 2026 vol. 123 no. 30

<https://www.pnas.org/toc/pnas/123/30>

[New issue; No digest content identified]

PNAS Nexus

Volume 5, Issue 7, July 2026

<https://academic.oup.com/pnasnexus/issue/5/7>

[New issue; No digest content identified]

Prehospital & Disaster Medicine

Volume 41 - Issue 1 - 2026

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 207 June 2026

<https://www.sciencedirect.com/journal/preventive-medicine/vol/207/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

Volume 293, Issue 2075 July 2026

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

Public Health

Volume 255 June 2026

<https://www.sciencedirect.com/journal/public-health/vol/255/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 18, Issue 2, July 2025

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2026, Vol. 29, No. 1

<https://karger.com/phg/issue/29/1>

[Reviewed earlier]

Public Health Reports

Volume 141 Issue 3, May/June 2026

<https://journals.sagepub.com/toc/phrg/141/3>

[Reviewed earlier]

Qualitative Health Research

Volume 36 Issue 7, June 2026

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

Research Ethics

Volume 22 Issue 3, July 2026

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 01 Aug 2026]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest Articles

30 Jul 2026

[Diphtheria in the Americas: strengthening routine immunization, surveillance, and outbreak readiness](#)

Intelligence Brief | English |

30 Jul 2026

[El Niño in the Americas, 2026–2027: public health risks and preparedness priorities](#)

Intelligence Brief | English |

Risk Analysis

Volume 46, Issue 7 July 2026

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 01 Aug 2026]

[No new digest content identified]

Royal Society Open Science

Volume 13, Issue 7 1 July 2026

<https://royalsocietypublishing.org/toc/rsos/current>

[Reviewed earlier]

Science

Volume 393| Issue 6810| 30 Jul 2026

<https://www.science.org/toc/science/current>

Policy Forum

[Rigor is not readiness: The PERL framework for evidence-based policy](#)

BY Christopher Cotton

30 Jul 2026: 463-465

Policy Evidence Readiness Levels help decision-makers assess evidence maturity and uncertainty

Abstract

Over the past three decades, the open-science movement and economics' credibility revolution have brought the rigorous methods of clinical trials to the social and behavioral sciences ([1](#), [2](#)). Better evidence should drive better policy. Yet interventions with promising effects in early studies routinely have little, no, or even negative impact when scaled ([3](#)). Often, an initial study is treated as proof that "it works," even when substantial uncertainty remains. The social and behavioral sciences adopted rigorous methods from clinical medicine but missed a deeper lesson that a mature, cumulative evidence base, rather than any individual study, should be the standard for informing policy. Policy Evidence Readiness Levels (PERLs), discussed here, are a framework for classifying evidence maturity and clarifying what actions it supports.

Science and Engineering Ethics

Volume 32, Issue 4 August 2026

<https://link.springer.com/journal/11948/volumes-and-issues/32-4>

[Scientific Objectivity and the Pursuit of the Public Good](#)

Sadie Hundemer, Jamie Loizzo, S. B. Paxson

Original Research/Scholarship Open access 02 May 2026 Article: 33

Science Translational Medicine

Volume 18| Issue 860| 29 Jul 2026

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 01 Aug 2026]

[No new digest content identified]

Social Science & Medicine

Volume 398 June 2026

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/398/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 01 Aug 2026]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 47, Issue 4 August 2026

<https://link.springer.com/journal/11017/volumes-and-issues/47-4>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 72 July–August 2026

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/72/suppl/C>

Editorial Open access

[Lethal hantavirus at sea: Infectious disease outbreaks on cruise ships and limits of preparedness](#)

Alimuddin Zumla, Brian McCloskey, Giuseppe Ippolito, Tieble Traore, ... Alfonso J. Roriguez-Morales
Article 102989

Research article Open access

[Outbreak preparedness and response in a globalized world: are we ready?](#)

Francesca F. Norman, David Brett-Major, Chiara Sepulcri, Emmanuel Bottieau, ... Kevin O'Laughlin
Article 103002

Tropical Medicine & International Health

Volume 31, Issue 7 Pages: 769-952 July 2026

<https://onlinelibrary.wiley.com/toc/13653156/current>

OPINION

Global Donor Fatigue and Its Impact on Vaccination Coverage in Africa: Challenges and the Path Forward

Michael Sarfo, Daniel Akuamoah Asirifi, John Kwame Agbenyeavu, Kwaku Obeng Boateng, Nelson Obeng, Sandra Konadu Bonnah, Betelhem Abebe Andargie, Gilbert Eshun

Pages: 769-771

First Published: 05 April 2026

Vaccine

Volume 87 01 Aug 2026

<https://www.sciencedirect.com/journal/vaccine/vol/87/suppl/C>

[Reviewed earlier]

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 01 Aug 2026]

Review

Exploring the Use of Storytelling in Vaccination: A Scoping Review

Marthe Bogne Penka, et al.

Vaccines 2026, 14(8), 665; <https://doi.org/10.3390/vaccines14080665>

29 July 2026

Introduction: Storytelling is gaining interest as a potentially useful research and communication approach in health. However, there remains a huge gap in synthesized evidence in relation to its use in vaccination. We set out to map existing evidence..

Systematic Review

Mapping the Global Landscape of Vaccine Acceptance Among the General Population from 2009 to 2024: A Systematic Review Across COVID-19 Pandemic Phases, Vaccine Categories, and Economic Strata

Madan Khatiwada, et al.

Vaccines 2026, 14(8), 663; <https://doi.org/10.3390/vaccines14080663>

28 July 2026

Background: Vaccine acceptance is a fundamental prerequisite for uptake, which may vary over time in response to contextual and vaccine-specific factors and major global disruption. This systematic review and meta-analysis evaluated global trends and...

Systematic Review

Systematic Review of Pharmacist-Administered Paediatric Vaccinations in Low- and Lower-Middle-Income Countries

Kimberly McKeirnan, et al.

Vaccines 2026, 14(8), 661; <https://doi.org/10.3390/vaccines14080661>

27 July 2026

Background: An estimated 25 million children globally miss routine vaccinations each year, with 14.3 million classified as zero-dose and the majority residing in low- and lower-middle-income countries (LMICs). Pharmacies are recognised as accessible...

Perspective

[Equity and Pandemic Influenza Vaccine Response: The PIP Framework as a Model for an Efficient Pandemic Influenza Response Through Equitable Vaccine Access](#)

Kate S. Rawlings, et al.

Vaccines 2026, 14(8), 653; <https://doi.org/10.3390/vaccines14080653>

23 July 2026

Equity is fundamental to an effective pandemic vaccination response, yet the COVID-19 pandemic demonstrated how inequitable access, driven by purchasing power and delayed supply for low- and middle-income countries (LMICs), prolonged transmission and...

Value in Health

August 2026 Volume 29 Issue 8 p1329-1538

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

World Medical Journal – Official Journal of The World Medical Association

Nr. 4, December 2025, vol. 71

<https://www.wma.net/publications/world-medical-journal/>

[Reviewed earlier]

World Development

Volume 205 September 2026

<https://www.sciencedirect.com/journal/world-development/vol/205/suppl/C>

[Reviewed earlier]

.....

.....

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

Pre-Print Servers

arXiv

<https://arxiv.org/>

[Accessed 01 Aug 2026]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Computational Engineering, Finance, and Science; General Literature; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

arXiv:2607.22607 [pdf, other]

[The Clinical Trial Pipeline Reveals the Next Wave of Artificial Intelligence in Healthcare: A Multidimensional Analysis of 8,532 Registered Studies](#)

Lior Rokach

The prospective clinical evaluation of artificial intelligence in medicine has expanded rapidly, but the global AI clinical trial landscape remains incompletely characterized. We systematically identified AI-related trials registered in CT.GOV [this http URL](#) using a broad keyword search followed by an LLM-based classifier. Each trial was classified across seven dimensions: clinical function, data modality, specialty, AI integration and autonomy, workflow position, translational maturity, and epistemic role.

We identified 8,532 AI clinical trials across 32 specialties, with 80% registered from 2019 onward and 30.5% using a randomized controlled design. Imaging-based AI was the largest modality, with 2,475 trials (29%), while clinical text and NLP trials increased seven-fold between 2018 and 2025. Prognostic AI (4,324 trials) slightly exceeded diagnostic AI (3,828 trials), suggesting a shift from disease detection toward risk stratification and trajectory prediction. Treatment recommendation remained less developed, with 768 trials (9%). Translational maturity remained limited: 3,259 trials (38%) were retrospective validation studies and 1,802 (21%) were silent prospective evaluations, indicating that much of the pipeline still produces algorithmic rather than clinical evidence.

Only 184 trials involved Level 4 semi-autonomous or closed-loop AI, 68% of which focused on glucose management. Multimodal AI accounted for 33.6% of trials, mainly combining imaging, omics, physiological signals, and wearable data. These findings indicate that clinical AI has moved from retrospective development to prospective evaluation, but not yet to adequately powered, geographically representative, long-term outcome trials. Future progress will depend on closing gaps in trial scale, specialty coverage, geographic representation, and translational maturity.

[arXiv:2607.24814](#) (cross-list from cs.AI) [[pdf](#), [html](#), [other](#)]

Aletheia: An Offline-First Clinical Decision Support System for Differential Diagnosis in Low-Resource Healthcare Settings

Joseph Walusimbi, Ann Move Oguti, Abubakhari Sserwadda, Precious Boss Kasasira, Charles Brian Okoboi

Comments: 8 pages, 11 figures, 4 tables

Access to specialist clinical expertise remains severely limited across sub-Saharan Africa, where physician-to-patient ratios can fall below 1:25,000 in rural settings. Existing AI-assisted diagnostic tools predominantly require reliable internet connectivity and high-specification hardware, rendering them impractical for frontline healthcare workers in district hospitals and health centres. This paper presents Aletheia, an offline-first clinical decision support system designed for low-resource healthcare contexts across sub-Saharan Africa. Aletheia is built upon Qwen2.5-3B-Instruct, fine-tuned using Quantised Low-Rank Adaptation (QLoRA) on a curated dataset of 27,000 clinical reasoning samples spanning 50 disease conditions with elevated prevalence in East Africa. Evaluation demonstrates a Top-1 diagnostic accuracy of 80.0%, Top-3 accuracy of 100.0%, BERTScore-F1 of 0.909, and METEOR of 0.467 across ten representative clinical case categories. The system achieves an Expected Calibration Error (ECE) of 0.275 and passes the Africa Deep Tech Challenge 2026 (ADTC 2026) memory budget constraint of 7 168 MB, achieving a peak inference RAM of approximately 3 630 MB on the standardised benchmark laptop. These results demonstrate the feasibility of deploying large language model-based clinical reasoning at the primary care level in resource-constrained settings without cloud infrastructure.

New - bioRxiv

<https://www.biorxiv.org/content/early/recent>

[Accessed 01 Aug 2026]

[Filters: *Bioengineering, Evolutionary Biology, Genetics, Genomics, Neuroscience, Synthetic Biology*]
Website not fully responding at inquiry...timing out from sequential citation exploration...exploring workaround options]

Evolutionary Dynamics of AI, Politicization, Contestation, and Trust in Science Funding

Animesh Ray

bioRxiv 2026.07.28.741134; doi: <https://doi.org/10.64898/2026.07.28.741134>

Abstract

Economic stability and progress in modern technological societies depend on vigorous and independent public funding of science and engineering research. When peer review or funding decisions are perceived as politically directed, scientists, funding agencies, and the public react in coupled and conflicting ways. We describe an evolutionary game-theoretic model to analyze how perceived political interference in science funding affects the interrelated behaviors of scientists, funding agencies, and the public. The model simulates scientists choosing to refuse peer reviews and retaliate, agencies responding by adopting AI-assisted review and altering reviewer pay, and the public accepting or rejecting these AI systems. Through numerical simulations, five principal findings are identified: (1) Operational capacity and institutional legitimacy are governed by separate conditions and can fail independently. (2) Legitimacy of the process is bistable, meaning final states are determined by the public's acceptance of AI. (3) Since the career cost for researchers refusing to review is generally low, resistance/retaliation cascades can readily ignite, leading identical institutions to entirely opposite fates. (4) Increasing reviewer pay only stabilizes participation within a strict budget-solvency frontier, and emergency pay can paradoxically erode the legitimacy it aims to protect. (5) Finally, finite-population simulations reveal that baseline scenarios partition into either legitimacy recovery without capacity or joint failure, confirming that the fundamental separation of capacity and legitimacy outcomes is a dominant structural feature driven primarily by initial scientific resistance and politicization levels. This theoretical work quantifies issues for future work in science policy.

medRxiv

<https://www.medrxiv.org/content/early/recent>

[Accessed 01 Aug 2026]

[Filter: All articles]

Website not fully responding at inquiry...timing out from sequential citation exploration...exploring workaround options]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 01 Aug 2026]

[Filter: All articles]

No new digest content identified.

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

No new digest content identified.

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 01 Aug 2026]

No new digest content identified.

* * * *

Think Tanks

Brookings [to 01 Aug 2026]

<http://www.brookings.edu/>

Research, Events

Research

A growing effort to restrict immigrants' access to public benefits

Assessing the federal actions affecting immigrants and their families

Mark H. Greenberg

July 24, 2026

- The Trump administration has initiated a multi-front effort to restrict access to a wide range of public benefits, assistance and services for non-citizens. The administration often frames its actions as focused on illegal immigrants, but the efforts will affect access to benefits and services for a much larger group, including U.S. citizens and citizen children.
- One set of restrictions were enacted when last year's One Big Beautiful Bill Act narrowed eligibility for SNAP, Medicaid, Medicare, ACA premium tax credits, and the Child Tax Credit. The changes primarily affect lawfully present immigrants rather than unauthorized immigrants, because unauthorized immigrants were already ineligible.
- The other efforts have flowed from a dramatic "reinterpretation" of requirements of federal law enacted by Congress in 1996. The 1996 law specified when groups of non-citizens would be eligible for "federal public benefits," and also said these restrictions would not apply to benefits necessary for the protection of life or safety. The administration has acted to broaden what counts as a "federal public benefit," and access to services and assistance needed for the protection of life or safety. Courts have limited implementation of these provisions while litigation is ongoing.
- Under a July 2026 public charge rule, when a person is seeking to become a lawful permanent resident, officials will be expected to consider any use of means-tested benefits by the individual or their children in support of a finding that they are "likely to become a public charge." The administration estimates roughly 1.3 million people will disenroll from or forego enrolling in benefits programs and a \$13 billion annual reduction in program expenditures, because eligible citizens and non-citizens will avoid benefits participation due to the rule.

Center for Global Development [01 Aug 2026]

<https://www.cgdev.org/>

All Research

No new digest content identified.

Chatham House [to 01 Aug 2026]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events

No new digest content identified.

Council on Foreign Relations [01 Aug 2026]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 01 Aug 2026]

<https://www.csis.org/>

Reports [Selected]

Aurélia Nguyen, CEPI: "Vaccines will be part of the solution" to the Bundibugyo Ebola outbreak

July 23, 2026

Aurélia Nguyen, Dep. CEO of CEPI (Coalition of Epidemic Preparedness Innovations) shares her unusual personal and career story, including working with Andrew Witty at GSK, and with Seth Berkley at GAVI during Ebola in West Africa 2014-2015 and later during the COVID-19 pandemic when she managed the COVAX facility. "It was incredibly difficult." CEPI's 3.0 strategy focuses on viral families; technologies and platforms; and networks to rapidly conduct clinical trials and begin manufacturing. CEPI swung rapidly into action with the advent of the Bundibugyo Ebola outbreak in Ituri, DRC. It struck a promising \$50 million partnership with the Department of State in support of its work to accelerate development of four vaccine candidates. Clinical trials are beginning and will advance in the fall in the hot zone in eastern DRC. Mistrust and insecurity require intensive community engagement. Even with US and EU support, CEPI still strives to fill an estimated \$130 million gap over the next 6-9 months. Her biggest worry? Cases have doubled in just 23 days. We are not yet able to gauge the true scale of the outbreak.

IS Global [to 01 Aug 2026]

<https://www.isglobal.org/en/press>

Newsroom

No new digest content identified.

McKinsey Global Institute [to 01 Aug 2026]

<https://www.mckinsey.com/mgi/overview>

Featured Research

No new digest content identified.

ODI [Overseas Development Institute] [to 01 Aug 2026]

<https://odi.org/en/publications/>

Publications

No new digest content identified.

Pew Research Center [to 01 Aug 2026]

<https://www.pewresearch.org/>

Latest Publications

No new digest content identified.

Rand [to 01 Aug 2026]

<https://www.rand.org/pubs.html>

Published Research [Selected]

Expert Insights Jul 31, 2026

Principles for Communicating the Risks of Mirror Life

This paper presents principles for communicating to the public and specific audiences about the risks of mirror life—a hypothetical life form, such as a mirror bacterium, that could pose catastrophic danger to humans, animals, and plants.

Research Jul 31, 2026

A U.S. Strategy to Prevent the Creation of Mirror Life

The authors of this report describe a strategy for the United States to prevent the creation of mirror life by anyone, anywhere.

Urban Institute [to 01 Aug 2026]
<https://www.urban.org/research>
New Research Publications - Selected
No new digest content identified.

World Economic Forum [to 01 Aug 2026]
<https://agenda.weforum.org/press/>
Media [Selected]
No new digest content identified.

.....
.....

Public Consultations/Calls for Inputs/Calls for Papers

WMA - Declaration of Taipei Revision Launched [Ongoing]

...The Declaration of Taipei tries to achieve a balance between the rights of individuals giving their tissue or data for research and other purposes based on confidentiality and privacy rules while at the same time recognising that health data has become a very powerful tool for increasing knowledge.

In analysing the scenarios that already exist for the use (and misuse) of health data and biobanks, we came to the conclusion that the major risk scenarios may not result from science, but from the commercial, administrative or political use of such data. Limiting our guidelines to research only would have left us blind to the imminent risk of abuse from outside the field of medicine: commercialization, cost-cutting and potential political abuse.

Therefore, in contrast to the Declaration of Helsinki, this policy aims to address any use of health databases and biobanks excluding individual treatment and is not restricted to research. As physicians are the primary custodians of confidential health information, they feel an obligation towards their patients and other persons who entrust them with their data and specimens...

In April 2025, the WMA appointed a workgroup to initiate the revision process of this document. To encourage as much global participation in the revision process as possible, the WMA is collaborating with its members to host a series of regional meetings...

* * * *

Contents [click to move among sections]

- [*:: Milestones, Perspectives*](#)
- [*:: WHO*](#)
- [*:: Organization Announcements*](#)
- [*:: Journal Watch*](#)
- [*:: Pre-Print Servers*](#)

* * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2026. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation and industry resource members Janssen/J&J, Pfizer, Sanofi US, and GSK. (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*